Evaluating animal-free approaches to the testing of skin sensitisers by Eddin, Nora Naser
    
 
  
 
Title:      Evaluating animal-free approaches to the 
testing of skin sensitisers 
 
 
Name:      Nora Naser Eddin 
 
 
 
 
This is a digitised version of a dissertation submitted to the University of 
Bedfordshire.  
It is available to view only.  
This item is subject to copyright. 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
Evaluating Animal-Free Approaches to the 
testing of skin sensitisers 
 
by 
Nora Naser Eddin 
 
 
 
2016 
University of Bedfordshire 
2 
 
 
Evaluating Animal-Free Approaches to the 
testing of skin sensitisers 
 
 
 
by 
Nora Naser Eddin 
supervised by Dr Zheying Zhu 
 
A thesis submitted to the University of Bedfordshire in partial fulfilment of the 
requirements for the degree of Master of Philosophy 
 
 
November 2016 
 
 
 
3 
 
Academic Thesis: Declaration Of Authorship 
 
I, Nora Naser Eddin 
declare that this thesis and the work presented in it are my own and has been generated by 
me as the result of my own original research. 
 
Evaluating Animal-Free Approaches to the testing of skin sensitisers 
 
I confirm that: 
 
1. This work was done wholly or mainly while in candidature for a research degree at this 
University; 
 
2. Where any part of this thesis has previously been submitted for a degree or any other 
qualification at this University or any other institution, this has been clearly stated; 
 
3. Where I have cited the published work of others, this is always clearly attributed; 
 
4. Where I have quoted from the work of others, the source is always given. With the 
exception of such quotations, this thesis is entirely my own work; 
 
5. I have acknowledged all main sources of help; 
 
6. Where the thesis is based on work done by myself jointly with others, I have made clear 
exactly what was done by others and what I have contributed myself; 
 
7. Either none of this work has been published before submission, or parts of this work 
have been published as indicated on [insert page number or heading]: 
 
 
 
Name of candidate: Nora N. Eddin Signature: Nora N. Eddin 
Date: 10/11/2016 
 
 
 
4 
 
Evaluating Animal-Free Approaches to the testing of skin sensitisers 
 
by 
Nora Naser Eddin 
ABSTRACT  
With the implementation of the 7th Amendment of the EU Cosmetics Directive in 2013, 
Local lymph node assay (LLNA) assay can no longer be used for testing cosmetic 
ingredients. The current thesis focused on three aspects for further understanding and 
elucidating the sensitisation process in order to contribute to the reduction, refinement and 
replacement (“3Rs”) of the animal models with alternative non-animal approaches.  
The performed quantitative whole human skin proteome analysis was established and 
identified total of 260 proteins. The applied GeLC-MS/MS identified proteins with diverse 
biological functions, sub-cellular locations and involvement of toxicological pathways at 
cellular and molecular levels. 
An in chemico approach, utilising Top-down MS technique, was applied, using Apomyglobin 
as recombinant protein.  Results have shown a shift of the m/z  (mass/ charge) ratio towards a 
higher value after treating with an extreme sensitiser, 1-chloro-2,4-dinitrobenzene (DNCB), 
indicating  haptenisation .  Further results have shown more binding sites on Apomyglobin by 
DNCB at a physiological condition. 
An in vitro model utilizing qRT-PCR (real time quantitative polymerase chain reaction) was 
used to investigate the effect of chemicals with different potencies and binding mechanisms: 
DNCB (2,4- dinitrochlorobenzen) and Phthalic anhydride (PA) on GST Pi gene expression in 
HaCaT cells. Experimental data showed DNCB to be a more potent Nrf2 activator in 
comparison to PA.
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1. Anatomy and physiology of the skin  
 1.1.1  Function of the Skin  
The skin is the largest and heaviest organ in the body.  Its main function is to protect the body from 
mechanical injuries, variation in the ambient temperature, radiation, invasion of pathogenic 
microorganisms, and the effect of external chemicals. The thermal regulation of the body starts with 
the involvement of the skin via sweat and body hair movement. The skin is a sensitive organ 
enriched with nerve receptors that are able to detect many changes in the environment, leading to 
involuntary responses with the final outcome of protecting the body from any harm (Tončić et al., 
2011).  
The skin is composed of three main layers: epidermis, dermis and hypodermis (Montagna, 1974; 
Brohem et. al., 2010) 
 1.1.2. Epidermis  
The epidermis forms the outer layer of the skin, providing a waterproof barrier and determining the 
skin colour. It has a thickness of approximately 50 cells in areas of thin skin, and around 100 cells in 
areas of thick skin. The epidermis is approximately 0.1 mm thick, and has the ability to renew itself 
totally every 28 days. The cells composing the epidermis are mainly keratinocytes, melanocytes and 
Langerhans cells (also known as dendritic cells), which are antigen-presenting immune cells that 
protect against infections.  
The epidermis itself is made of few sub-layers. The deepest layer of the epidermis, located 
immediately above of the dermis -  is known as the Stratum basale. The Stratum basale is composed 
of cube-shaped cells: keratinocytes and melanocytes. Keratinocytes in this layer constantly undergo 
division for regeneration, which contributes to the skin renewal process. On the other hand 
melanocytes, also called protective cells, are responsible for the synthesises of melanin, an important 
pigment that determine the tones of the skin colour and protects from the UV-radiation of the Sun.  
The Stratum spinosum is the second layer of the epidermis, and is composed mainly of keratinocytes.  
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The third layer is Granulosum and it contain  of a protein called keratin. Keratin is tough, fibrous 
protein with a protective properties. The fourth epidermal layer is called the Stratum Lucidum; it is 
found in specific parts of the body such as fingertips, palms of the hands and soles of the feet. The 
fifth and top outer layer of the epidermis is called Stratum Corneum and it is composed of dead 
keratinocytes. This layer is continuously regenerated by the formation of new keratinocytes from the 
deeper layers. The Stratum Corneum and the keratinocytes are separated by epidermal lipids. The 
epidermal lipids perform adhesion between the skin cells. The keratinocytes and the epidermal lipids 
together form a waterproof layer, preventing water loss and keeping the skin moist. The surface of 
the Stratum Corneum appears to be slightly acidic with a pH range from 4.5 to 6.5. The acidic pH is 
maintained by the secretion of sebaceous and sweat glands to sustain the hardness of the keratin and 
to prevent the growth of harmful bacteria and fungi  (Tortora and Grabowski, 1993). 
 1.1.3. Dermis  
The Dermis is the middle skin layer, located between the epidermis and the hypodermis. This layer is 
2 mm thick and is responsible for maintaining the structure and resilience of the skin. The dermis is 
made of structural proteins called collagen and elastin, forming a mesh-like structure, as well as 
blood and lymph vessels, mast cells and fibroblasts surrounded by glycosaminoglycans (a gel-like 
substance). The glycosaminoglycans provide moisture to the epidermis and enable the collagen 
fibres to retain water.  The fibroblasts are cells that produce collagen and elastin, where as blood 
vessels in the dermis help with the body’s thermal regulation. Mast cells are specialised cells with an 
important immunological role and ability to trigger skin immune response as a result of contact with 
allergens and harmful microorganisms. 
 1.1.4. Hypodermis   
The Hypodermis is the inner skin layer, rich with fat tissues, hair follicles, blood vessels, 
sweat glands and connective tissues. The fat tissues help in regulation of body temperature, 
16 
 
shock absorption and the provision of nutrients and energy to surrounding cells (Millington 
and Wilkinson, 2009) (Siemionow and Einsenmann-Klein, 2016).  
 
 
Figure1. Schematic representation of the composition of the skin (Tortora and Grabowski, 1993)  
 
 1.1.5. Immune cells of the skin.  
 The skin is the primary barrier against physical insults and microbial pathogens.  
It represents a unique environment where immune cells interact with skin cells to keep tissue 
homeostasis and induce immune responses. A diverse and multifunctional immune cells 
populate the skin.  
In the epidermis a specialised subset of  Dendritic cells (DC) known as Langerhan cells (LC)  
sample antigens such as toxins. LC cells appear to have both anti-inflammatory and 
activatory role in the skin, depending on the event. DC cells in the derims are highly efficient 
of capturing dead cells, and presenting antigens such as viruses and other pathogens to the T 
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cells. DC cells can be described as the immune vehicle, that represent antigen to T cells, 
where T cells are the immune effectors. In healthy skin the amount of T cells is double in 
comparison with the T cells present in the blood. Most of them are T cells that have 
previously recognised Ag (antigens) and can be quickly reactivated. T cells in the epidermis 
are mostly CD8 + T cells, which as a result of their activation can kill target cells.  
T cells in the dermis are mostly CD4+ T cells, with a modulatory  role (reduce tissue 
destruction) as a result of the immune response. In addition, NK (natural killers), mast cells 
and eosinophil cells are present in the dermis and are involved in skin immune reactions.  
In the case of Ag invasion the keratinocytes presented in the epidermis start secreting AMP 
(antimicrobial peptide) that can kill bacteria directly and/or secrete  inflammatory mediators 
such as IL1 (interleukin 1) which activate DC cells and chemokines that recruit macrophages, 
T cells and neutrophils (different types of cells involved in the immune response). Activated 
DC cells migrates to the LLNA (local lymph node), representing the antigen to the available 
there naive cells which in turn become activated and turn into effectors T cells. Activated T 
cells return to the epidermis and kill the affected keratinocytes or secrete signals to recruit 
additional immune effectors cells. Following antigen clearance the memory CD8+ T cells 
remain in the epidermis to provide immunity for future encounters with the same antigen 
(Galli and Tsai, 2013). 
 
1.2.  Hypersensitivity and the use of cosmetics / personal care products 
Any substance that triggers an allergic response is referred to as an allergen. Allergens can be 
substances secreted by microorganisms; plants; animals; or any other naturally  occurring  chemical. 
The allergy can be caused by exposure to an agent in the atmosphere (pollen); contact with skin 
(cosmetics); ingestion (food) or injection (insect bite or drug) . Allergic hypersensitivity is an 
immune response by the body resulting from an exposure to a certain dose-specific stimulus, which 
may, however, be well-tolerated by other individuals. Different factors can affect the nature and 
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severity of an allergic reaction, such as rout of exposure, skin condition, degree of sensitisation in 
addition to various genetic factors which are not yet very well understood. Hypersensitivity can be 
considered both allergic and non-allergic. Non-allergic hypersensitisation, also known as "pseudo-
allergy," does not lead to an immune reaction due to contact with certain allergens. Allergic 
hypersensitivity appears when the individual develops an immune response as a result of contact 
with the allergen. Allergic hypersensitivity can be antibody-mediated or non-antibody-mediated. 
Antibody-mediated hypersensitivity involves antibodies such as IgE, IgG, IgM (immunoglobulins 
E,G and M), and mast cells, where the immune response can develop within hours. Allergic contact 
dermatitis belongs to the non-antibody-mediated hypersensitivity also known as cell mediated 
immune reaction (CMIR), which is regulated by the proliferation of T cells.   The immune response 
caused by non-antibody-mediated hypersensitivity usually develops within one to three days 
following exposure to allergens (Janeway et al., 2003). 
Immune reactions can be classified into four main groups, known as Types I, II, III and IV. 
Type I immune reaction known as an immediate hyper sensitivity that can develop typically 
within few minutes of the exposure to an antigen. This type of immune response is lead 
meanly by IgE (immunoglobulin E) and mast cells. Mast cells are type of granulocytes 
derived from myeloid stem cells. Mast cells play an important protective role from allergy, 
wound healing and defence against pathogens. 
Type II immune response is based on antibody binding to membrane- bound antigen leading 
to inflammation. This type of immune response usually develops within 20 min as a result of 
exposure to an antigen.  
Type III immune response takes place when the antibody binds to a soluble antigen forming 
immune complex. In this immune response the immune reaction develops within seven to ten 
hours as a result of antigen exposure. 
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Type IV immune response include cell-mediated reaction. The reaction evolves slower in 
comparison to the antibody mediated reactions usually within few days post exposure to an 
antigen. 
The allergen immune response can be divided into two main events: sensitisation event and 
reaction event. 
During the senstisation event the presence of antigen triggers the immune response by the 
activation of IgE antibodies alongside with T cells, B cells and macrophages. The induced Ig 
E antibodies bind to the tissue mast cells through the Fc mast cell receptors. The Fc's 
receptors on the surface of the mast cells have a very high affinity towards IgE antibodies.  
Re-exposure to the same allergen triggers the reaction event of the immunological response. 
The antigen is recognised by the mast-cell-bound-IgE antibody complex and attaches to it. As 
a result the large basophilic granules presented in the mast cells are released into the tissue, a 
process known degranulation. The released by the mast cells pharmacologically active 
compounds (mediators) can have different effect on different tissues as a result of the antigen 
exposure (Janeway et al., 2003). 
The market provides huge variety of different cosmetic and personal care products. Each product 
contains different substances that come into contact with the which in some cases lead to allergic 
reactions.  Many different substances are added to wide range of cosmetic products, detergents and 
personal care products to enhance the product's fragrance and quality.  The main allergenic 
substances available in cosmetic and personal care products have been listed by Schnuch et al.; in 
2004, around 5000 different substances were in use as fragrances in different cosmetics and personal 
care products (shampoo, body lotions, perfumes, crèmes, toothpastes). For example p-Phenylene 
diamine is a substance used in hair dyes and temporary tattoos (henna additives);  formaldehyde or 
formaldehyde liberators/resins, a substance used as a preservative in cosmetics; rubber products 
containing mercaptobenzthiazol which triggers a type IV hypersensitivity immune response. To 
20 
 
ensure product safety to customers, all cosmetics industries are required to undertake toxicity testing 
on all new and current chemicals (Schnuch et al., 2004). 
There are two main approaches to the reduction of contact allergies. Firstly, testing of the substances 
used in the production of cosmetics and personal care products; more specifically, those substances 
that come into direct contact with the skin. Secondly, the use of available information to develop 
models which aim to predict more accurately the skin sensitisation potency of different substance 
(The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins, 
2014). 
 
 1.3.  Allergic contact dermatitis (ACD) 
Contact allergy, known as Allergic Contact Dermatitis (ACD), is a type IV delayed 
hypersensitivity reaction. It is considered to be a challenging immunological disease in the 
public health context, as it affects a large section of the public. It is based on environmental, 
domestic and occupational contact with chemicals, and affects up to 15-20% of the 
population of Europe.  The majority of cases belong to allergies caused by chemicals used in 
cosmetics and personal care products (Tončić et al. 2011). ACD is considered the second 
most widespread occupational illness. It entails an annual cost of up to $1  billion in terms of 
employment compensation, cost of medical treatment and lost working time (Anderson et al., 
2011). 
1.3.1. The mechanism of skin sensitisation  
Allergic Contact Dermatitis (ACD) is a type IV delayed hypersensitivity reaction, 
occurs after direct contact of the skin with allergens known also as haptens. Allergens are 
molecules small enough to pass through the epidermis and so reach the dermis . The haptens 
on their own are unable to trigger any immune response by the body. However, if the 
allergens (haptens), on reaching the dermis, bind covalently with local proteins, they form a 
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so-called protein-hapten conjugate (or complex), which in its turn as a complex can lead to 
allergic response. The extent to which the haptens are able to pass through the skin is known 
as their bioavailability.    
ACD process is based on the ability of an allergen to penetrate the skin and to bind to 
an endogenous epidermal protein, thereby forming a protein-hapten conjugate Some 
chemicals (pro-haptens) require enzymatic activation, where as other chemicals (pre-haptens) 
have to be oxidised in order to become active haptens, with the ability to bind to the proteins 
available in the skin.   This process is known as haptenisation. As a result of the protein 
hapten formation, the keratinocyte cells (KC) available in the epidermis are capable of 
producing a cocktail of pro-inflammatory cytokines as a response to a chemical stress. The 
protein-hapten conjugate (known also as modified protein) is recognised by the Langerhans 
cells (LC), which are a type of hapten-presenting immune cells. The Langerhans cells 
recognise the protein-hapten conjugate, engulf it and migrate to the nearest lymph node. The 
LC cells, having matured and migrated to the local lymph nodes present the protein hapten 
conjugate (or part of it) on its surface using MHC class molecule (major histocompatibility 
complex). The protein-hapten adduct is recognised by the CD4+ T helper cells (white blood 
cells with a crucial role in the body’s immune response). As soon as the recognition between 
the CD4+ T cells and the protein-hapten conjugate, now attached to the LC cells happens, the 
LC cells start to release IL-12 (interleukin 12). IL-12 causes the CD4+ to mature and 
differentiate, and form Th1 (T cell helper cells). The mature Th1 cells start releasing 
interleukin 2 (IL-2), causing proliferation of the Th1 cells. Th1 cells start secreting IFNγ 
(interferon gamma), which helps to activate macrophages and causes proliferation of T cells. 
Activated macrophages start releasing pro inflammatory cytokine (TNF, IL1, IL6) which 
causes more T cells to reach the areas affected by allergen. When the skin undergoes 
subsequent exposure to the same allergen, the T cells recognise the haptenised protein as a 
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foreign molecule and lead to skin inflammation ( local redness, edema and fever). (Goebel et 
al., 2012; Ryan et al., 2007; Saint-Mezard et al., 2004; Haniffa et al.,2015) (Figure 2).  
 
Figure 2. Simplified schematic representation of the induction phase of the sensitisation process: Allergen 
penetrates the epidermis (1), enabling covalent interaction with a protein (2) leading to the formation of 
complete protein-hapten conjugate, which interacts with keratinocytes (KC,) and (3) triggers dendritic cells 
(DC) activation and maturation to the lymph nodes (4). There, the antigen is presented to naive T cells. TC 
differentiates and proliferates in response to the antigen presence (5). Source: The Adverse Outcome Pathway 
for Skin Sensitisation Initiated by Covalent Binding to Proteins (2014).  
 
 
 Figure 2 shows the induction of skin sensitisation as a multi-stage process driven by 
several toxicity pathways including disposition, biotransformation, haptenisation and 
immune-reactivity in skin.  
The formation of protein-hapten conjugate is one of the key events in the skin sensitisation 
process. The ability of the hapten to covalently bind and modify a protein is due to the 
different physico-chemical properties amongst haptens and proteins. Haptens appear to act as 
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electrophiles this word is formed from the word “electron” and the Greek word philos (love), 
meaning that electrophiles have a strong tendency to attract electrons) 
 whereas some  proteins can act as nucleophiles (which donate electrons) due to the 
nucleophilic properties of their side chains. It is important to highlight the fact that the 
haptens (electrophiles) are unable to cause a skin sensitisation unless bound to a protein (a 
nucleophile) available in the skin (Aleksic et al., 2007)                                
Despite the importance and diverse functions of the skin, relatively little is known about its 
proteome composition. As the covalent modification of skin proteins by allergens plays a 
crucial role in the skin sensitising process, a full characterisation of the skin proteome, 
detailed understanding of the protein-hapten binding mechanism and the specificity of its 
reaction will lead to the development of new approaches in testing contact allergens (Aleksic 
et al., 2008).  
The key to the risk assessment of skin sensitisation is to understand the molecular 
pathways involved in the process. Although many details of hapten-modified protein immune 
recognitions and the complex pathophysiology of skin sensitisation have been clarified, 
several aspects remain unclear and require further investigation. In particular, detailed 
information on biotransformation and haptenisation on a molecular level is limited and 
remains as the most challenging area (Chipinda et al., 2011). 
The process of haptenisation is regarded as a crucial step in sensitising human T cells. 
 
1.4. Local lymph node assay (LLNA) 
Different in vivo models have been used to evaluate skin allergens by their toxicity and 
potency. Local Lymph Node Assay (LLNA) is the preferred method for evaluating sensitisers 
based on their potency developed in 1989. It is currently one of the most appropriate and 
successfully validated sensitisation test methods to evaluate chemicals with regards to skin 
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sensitisation based on the use of animal models. Local lymph node assay (LLNA) is the main 
and standard testing method to measure the skin sensitising potency of low molecular weight 
chemicals, and is performed on mice.  
The chemical undergoing risk assessment is injected into the ear of an animal model (mouse) 
for three subsequent days. At day six of the chemical exposure the mouse is injected with the 
radioactive nucleoside 3H-thymidine. Thymidine is an essential nucleoside for DNA 
synthesis, hence  Radioactively labelled thymidine can be used to determine the change in the 
number of lymphocytes produced. Based on this technique a chemical can be classified as a 
sensitiser if it has caused a threefold increase in the number of proliferate lymphocytes in the 
lymph nodes in comparison with a control (Anderson et al.2011) . The method determines the 
concentration of the chemical leading to sensitisation by measuring the proliferation of 
lymphocytes in the lymph nodes and hence classifying chemicals as strong, moderate, weak, 
irritant and non-sensitisers (Gerberick et. all 2007; Troutman et al., 2011). LLNA can provide 
reliable results based on quantitative and dose dependent data and predict chemical potency 
(Figure 3). Despite the benefits of using the LLNA assay, researches show that the assay has 
a few disadvantages, such as false positive results, in addition to the variation due to the 
animal model used and the ethical issues arising from the use of animal models (Anderson et 
al., 2011). 
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Figure 3. Overview of the local lymph node assay, in which a test substance is applied on the mouse ear for 3 
subsequent days, followed by injecting at day 6 into the tail vein with radioactively labeled thymidine (3H-
thymidine). Lymph nodes are removed and processed for measuring the amount of lymphocytes produced as a 
result of the exposure. Source: (Basketter, 2008) 
 
 
 
1.5.  The 7th amendment of the EU Cosmetics Directive in 2013 
The Global Cosmetics Market is predicted to reach $292 billion in 2017 due to the 
increase in the consumer income and changing people's life style (Figure.4).  
 
Figure. 4 Global cosmetics market is predicted to reach $265 billion in 2017. From 2012 to 2017 the 
Global cosmetic market is predicting 4.6 % increase. Source:  (Maheshwari, 2013) by RNCOS 
 
 
The Registration, Evaluation and Authorisation of Chemicals (REACH) has to assess 
thousands of chemical substances yearly for environmental and health risks. REACH was 
established in 2006 ( Regulation (EО) No 1907/2006 ), aiming to control any chemical 
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substances used in the EU market. The regulation aims to ensure a high level of human health 
and environmental protection ; to guarantee free movement of chemical substances in the 
European market;  to ensure that the necessary risk assessment of using the chemicals has 
been appropriately undertaken; to encourage the use of alternatives to the currently used 
methods for testing sensitisers and to promote innovation within and competitiveness of the 
European chemical industry ( REACH - Growth - European Commission, 2017). 
Skin sensitisation is one of the key endpoints for safety testing on cosmetic products 
before they are licensed.  
The proposed from the European Union (EU) Directive to ban the use of animal models for 
testing cosmetics and personal care products  was first issued in 1993. 
Cosmetic companies were asked to find alternatives to the currently used methods, 
such as LLNA, for testing the sensitisation potency of chemicals by 1998.  However, at that 
point the researchers had failed to develop alternative models that could replace  the available 
animal models, hence the deadline was extended by two more years.  
In 2003 the new Directive proposed a set of provisions where screening any 
developed cosmetic products and cosmetic ingredients on animals would be  banned.  The 
EU continued to work hard on establishing a total ban on the use of the animals as chemical 
testing models and in 2009 (6 years later), the ban entered into force in the EU.  
In March 2013 the ban was officially applied under the 7th amendment of the EU 
Cosmetics Directive. The ban included two aspects: firstly a testing ban, where cosmetic 
products and ingredients are prohibited for testing on animals. The second aspect referred to a 
marketing ban, stated that any cosmetics products and ingredients tested on animals are 
prohibited for the EU market (Ban on Animal Testing - Growth - European Commission, 
2017). 
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With the implementation of the 7th amendment of the EU Cosmetics Directive in 
2013, the currently powerful LLNA technique for safety testing of skin sensitisation on 
animals can no longer be used for chemical ingredients used in cosmetics or personal care 
products. On the other hand REACH has the aim to assess approximately 30,000 chemical 
substances which need to comply with this ban and undergo alternative to the in vivo 
examination (REACH - Growth - European Commission, 2017). 
 Therefore there is an urgent need to reduce, refine and replace (the “3 Rs”) animal 
models with alternative non-animal approaches. Currently there are a few alternative 
approaches to the animal methods for testing chemicals, known as in chemico, in vitro, in 
silico; some have been validated and others are still under study.  In addition to the above, 
there is also the possibility of developing integrated testing strategies with a combination of 
different mechanistically-based testing models (in chemico/in silico/in vitro), to test toxicities 
including skin sensitisation (Troutman et al, 2011; Basketter, 2012).  
 
1.6. Current approaches for testing skin sensitisers.  
Hypersensitivity is a complex response by the body to allergens that can be analysed and 
described on a molecular and cellular level.  The pathway of events leading to the body’s 
response to stimuli  is known as the Adverse Outcome Pathway (AOP). Many research groups 
are working extensively on establishing non-animal models for testing sensitisers by focusing 
on the different AOP key events. AOP includes four main key events, detailed study of which 
would contribute to the identification and characterisation of skin sensitisers. The first key 
event of AOP is the bioavailability, the ability of the allergen to penetrate the skin, pass 
through the epidermis and reach the dermis. All these events can be explained with a detailed 
knowledge of the physico-chemical features of the skin.  Antibody mediated and cell-
mediated immune responses lead to the activation of T cells by activation of class I and II 
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MHC molecules located on the surface of antigen-presenting cells such as LC cells. 
However, this event can take place only if the body’s immune system is able to recognise the 
skin-penetrating allergens. As allergens (haptens) are small molecules, they can lead to an 
immune response only if they bind to proteins available in the skin, thereby forming a 
protein-hapten adduct (this is the second event of the AOP). Allergens can be reactive and 
directly bind to skin proteins, while in some cases allergens need to be activated either by 
enzymatic modification (pro-haptens) or oxidative modification (pre-haptens) in order to 
induce a chemical response. The third AOP key event is the activation of LC cells that 
upregulate the expression of cell surface biomarkers (CD83, CD86) and/or monitoring of DC 
gene expression at the transcriptional level as a result of chemical sensitisation. Many DC 
cell line based assays have been developed using the U937 myeloid cell test, the human Cell 
Line Activation test (h-CALT), and the U937/CD86 assay, evaluated by different leading 
cosmetic companies (L'Oreal, P&G, Shiseido, Kao, Henkel). The final event of the AOP 
pathway is measurement of the proliferation of T cells in the local lymph nodes, where LLNA 
is still considered to be the leading approach for quantitative sensitisation endpoint (The 
Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins, 
2014; Maxwell and MacKay, 2011; Aeby et al., 2007).  
The OECD (Organisation for Economic Co-operation and Development) is a multinational 
organisation, established in 1961, with a membership from 35 different countries. The main 
aim of the OECD is to improve economic outcomes / to improve economic situations across 
the world, by assuring the social well-being of the population. OECD tries to seek solutions 
to common international problems of the current century in broad economic, social and 
environmental areas, including the safety of chemicals (About the OECD - OECD, 2017). 
OECD in regards to the AOP for skin sensitisation has reported that various non 
animal approaches are at different stages of acceptance, validation, development and use. 
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However with the current data, it is impossible to rate the chemicals on their sensitisation 
potency (Corsini et al., 2016).  
The main three studied alternative to the animal approaches are In chemico; in vitro 
and in silico (Figure 5). 
The In chemico approach is developed on the basis of studying the mechanism of 
haptenisation, i.e. the ability of the allergen (hapten) to penetrate and bind to proteins 
available in the skin. This approach is built on the basis of the use of recombinant proteins or 
peptides (sequence of a amino acids ) as a model for studying chemical potency. This 
approach is based on measuring peptide depletion as a result of protein-hapten formation 
and/or measuring the reactivity of the proteins towards the allergens, after the allergens have 
been metabolised by enzymes or by oxygen (prohaptens and prehapten respectively). The in 
chemico approaches are simple and easy to perform; the protein-hapten formation can be 
easily explained with the knowledge of the organic chemistry.  Despite the above advantages 
this approach faces a very important drawback, the discrepancy between the behaviours of 
the proteins in the real system (in the body) and when isolated (in a tube), where it is not 
possible to consider any interactions between the proteins under analysis and those in the 
surrounding body tissues (Gerberick et al., 2007; Gerberick et al., 2009; Troutman et al., 
2011; ). 
The In vitro approach is based on measuring the complex mechanism of the body 
response on a molecular, cellular and tissue level as a result of the sensitisation process. 
Studying the interaction between the allergens and the different compartments of the immune 
system underlies the in vitro approaches. Keratinocytes (KC cells) play a crucial role in 
triggering the immune response as a result of contact with sensitisers. KC cells produce a 
large quantity of inflammatory cytokines that can alert LC cells to the presence of allergens. 
In vitro assays aim to measure any chemical-induced changes as a consequence of a chemical 
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exposure. On the other hand measuring the maturation of Dendritic cells has been intensively 
studied in the last 20 years, by measuring changes in cell surface receptor expression. T cell 
proliferation is another sensitisation endpoint covered within the in vitro approaches, 
following co-culture of DC or LC with chemical sensitisers (Maxwell and MacKay, 2011). 
The In silico approach is based on the use of different computer programs to predict 
skin sensitisation. The computer programs are usually developed based on information (data) 
gathered from experiments performed either in chemico, or in vitro, or both. Following the 
established predictions, scientists can make assumptions and apply these assumptions to other 
chemicals in order to categorise them as sensitisers or non-sensitisers.  “Structure Activity 
Relationship” (SAR) is an example of an in silico approach, which studies the relationship 
between the chemical structure of the allergens and the biological activities of proteins as a 
result of exposure to that allergen. An in silico model additional to SAR is the is the so-called 
“Quantitative Structure Activity Relationship” (QSAR), which uses statistical methods to 
analyse biological data. The main limitation of such an approach is that it is based on 
predicting “yes or no” sensitising outcomes, without physically interpreting the chemical 
compound’s behaviours Figure 5 ( Thyssen et al., 2012)  
 
Figure 5. Summary of the currently non-animal approaches for sensitisation assessment  
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The development and evaluation of non-animal models suitable for the categorisation 
of skin allergens is one of the most current strategies at the European Union Reference 
Laboratory for Alternatives to Animal Testing (EURL ECVEM), of which the intention is to 
finalise and validate the existing models over the next few years (Casati et al., 2013; Zuang et 
al., 2013).  
More than 4000 chemicals with a molecular weight below 500 Da have been proven 
to cause Allergic Contact Dermatitis ( ACD). It is crucial from a toxicological point of view 
to estimate and categorise the potency of these chemicals in order to determine their 
hazardous effect on human health.   
EURL ECVEM was established in 2011 with the aim to scientifically validate the 
proposed non-animal models for testing skin sensitisers. The methods which have so far been 
validated for testing chemical potency by EURL ECVEM are DPRA (Direct Peptide 
Reactivity Assay), an in chemico method, which measures the depletion of lysine and/or 
cysteine peptides in the presence of chemicals; the KeratinoSen assay, an in vitro assessment 
which measures the expression of the luciferase gene as a result of the activation of the 
Keap1-Nrf2-ARE pathway using HaCaT cells. The third method validated by EURL 
ECVEM is the Human Cell Line Activation Test (h-CLAT), an in vitro method based on 
measuring the expression of surface biomarkers such as CD86 and CD84 using human 
monocytic leukemia cells (THP-1) (Figure 6) (Corsini et al., 2016). 
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Validated non-animal methods for testing sensitisers
In chemico method In vitro method
ARE-Nrf2 luciferase test 
method: KeratinoSens
Direct Peptide Reactivity 
Assay (DPRA)2
Human Cell Line 
Activation Test (h-
CLAT)3
EURL ECVAM (2013)
JaCVAM(2015)
EURL ECVAM (2014) EURL ECVAM (2015)
Figure 6.  Current evaluated and validated non-animal models for categorization of skin sensitisers by European 
Union Reference Laboratory for alternatives to animal testing  
 
 
1.7. Aims and objectives. 
A schematic representation of the scheme of the current work and a summarized 
description of each outcome and how it is to be achieved is represented in Figure 7.  The 
current research project was established through a series of experiments aiming to contribute 
to the “3 Rs” (Refine, Reduce and Replace) the animal as a model for assessing skin 
sensitisers. 
1. To determine and characterise constitutively expressed proteins in the whole human 
skin by utilising the established label free quantitative GeLC-MS/MS proteomic 
technique. 
2. To develop a new in chemico approach to examine intact protein-hapten interactions 
and identify potential new haptenisation pathways by using the top-down mass 
spectrometry technique. 
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3. To investigate mRNA expression of metabolic enzymes (Phase II) induced by 
chemical sensitisers with different binding mechanisms and sensitising potency over 
time course using quantitative polymerase chain reaction (qRT-PCR). 
 
Figure 7. Schematic overview of the current research project.   
 
1. 8. Main hypothesis  
A detailed study of the human skin proteome and possible improvements to 
existing non animal approaches (in chemico, in vitro) can help in the aim of refining, 
reducing and replacing the use of animals as an existing model for chemical risk 
assessments. 
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Chapter 2 
Human skin proteome profiling 
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2.1. Introduction   
Skin cells are able to grow, renew themselves and differentiate throughout their life, and 
provide  physical barrier to the environment, in that they limit the inwards and outward 
passage of water, electrolytes and various substances, while providing protection against 
microorganisms, ultraviolet radiation, toxic agents and mechanical injuries. (Zaidi, 2010). 
Despite the importance and diverse functions of the skin, relatively little is known about its 
proteomic composition. As the covalent modification of skin proteins by allergens plays a 
crucial role in the skin sensitising process, a clear picture of  the protein composition of the skin, 
and identification of the toxicological pathways involved could lead to the development of new 
approaches to testing contact allergens (Aleksic et al., 2008). 
Quantitative and qualitative characterization of the skin proteome could provide detailed 
information about the structure and function of skin proteins, leading to better explanation of 
the skin changes in response to sensitisers. The current research is particularly interested in 
those skin proteins involved in Toxicity pathways that could be determined as “specific 
markers” in response to chemical exposure.  
GeLC-MS/MS, also known as SDS-PAGE-gel digestion-LC-MS/MS is a powerful technique 
for differential analysis of complex protein mixtures.  Briefly, the protein complex mixture is 
separated based on the size of the proteins using  SDS-PAGE Polyacrylamide gel followed by 
protein digestion and NanoLC-MS/MS. The received data of each individual fraction are 
searched against a database, leading to identification and quantification of the whole complex 
protein sample, an approach already successfully applied by different research groups (Zhu et 
al., 2008b; van Eijl et al., 2012; Parkinson et al., 2014). Van Eijl and co-worker successfully 
applied this approach in identifying and comparison studies between xenobiotic metabolic 
enzymes of whole human skin and available in vitro skin models. In addition, Parkinson and 
his research group worked out and analyzed whole human skin proteome which identified 
150 skin proteins(Parkinson et al.,2014). 
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The complexity of the sensitisation process and the diversity of skin proteins directed many 
of the current in vitro researches to be focused on the different AOP (adverse outcome 
pathways) leading to the toxicity endpoint. Identifying, studying and analyzing the whole 
human skin proteome in addition to the explication of toxicity pathways involved therein, 
could explain in detail the skin responses toward chemicals and hence distinguish between 
sensitisers and non-sensitisers (Vandebriel et al., 2010; Van den Veer et al., 2012). 
In this research, detailed quantitative and qualitative description of the whole human skin 
proteome was provided by utilizing the well-established GeLC-MS/MS techniques. The 
identified proteins were subjected to further analysis in a toxicological context with the aim  
of finding “markers” that may work as cellular endpoints for skin sensitisers  at the level of 
transcriptomics and/or proteomics. 
Furthermore, little is known about which proteins in the human skin are targeted by 
haptens, due to the absence of information about the whole human skin proteome. A more 
detailed picture and characterisation of the human skin proteome would lead to the development 
of better approaches for testing cosmetics and personal care products (Aleksic et al., 2008). In 
the current project, protein separation, identification and quantification in the subcellular 
fractions of the human skin samples were performed by using label-free quantitative 
proteomics GeLC-MS/MS. This methodology was established by Zhu et al., 2008a and has 
been successfully applied in the Cosmetics Europe Skin Metabolism project by van Eijl et al., 
2012. This technique allows assessment of the global expression profile of proteins, unlike 
other approaches. 
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2.2. Materials and method 
 
2.2.1. Sample preparation (performed at University of Bedfordshire) 
Samples of abdominal human skin homogenate fractions from healthy females, aged between 
30 and 60 , and having undergone reduction mammoplasty (n-8) were obtained from 
Biopredic International (Paris, France). The abdominal skin homogenate samples represented 
two different races: four Caucasian and four African.  To my knowledge there is no record 
provided by Biopredic International (Paris, France) in regards to whether any of the donors 
has suffered from any allergic reactions (Human skin certificate of analysis, see appendix 
figure 22). The homogenates were provided in corresponding buffer (10mMTris-Cl, 1mM 
EDTA, 250mM Sucrose, protease inhibitors, pH 7.4) and stored in liquid nitrogen for further 
usage.  
The 8 samples were ultracentrifuged at 10 000 rpm for 25 min at 4˚C for the separation of the 
soluble S9 and insoluble non-S9 fractions. One of the technical difficulties faced during the 
experiment was to solubilise the proteins in the non S9 fractions. To achieve that the 
insoluble Non S9 fractions were dissolved in 9M Urea/2 %Chap followed by centrifugation 
at room temperature for 20 min at 3000 rpm. The insoluble non-S9 fractions were dissolved 
in 9M Urea/2 %Chap followed by centrifugation at room temperature for 20 min at 3000 
rpm. The supernatant was collected and used to determine the protein concentration using 
BCA assay. 
 
2.2.2. Estimation of protein concentration (performed at University of Bedfordshire) 
The BCA assay method (Sigma Aldrich, UK) using bicinchoninic acid was performed to 
determine the protein concentration of the 8 samples (S9 and non-S9 fractions separately). 
BSA (bovine serum albumin), used as a standard was prepared as per the manufacturer’s 
requirements. 25 μl of each standard and unknown samples in replicates were added to a 96 
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microplate well. 200 μl of working reagent (prepared according to the  manufacturer’s 
methodology) was added to each well and the plate was mixed on a shaker for 30 min. The 
plate was covered and incubated at 37 °C for 30 min. Absorbance was measured at 570 nm. 
A standard curve was plotted showing absorbance at 570 nm vs. concentration in μg/ml. The 
plotted graph was used to determine the protein concentrations of the unknown samples. 
 
2.2.3. GeLC-MS/MS sample preparation (performed at University of Bedfordshire) 
The whole protein of S9 and the non-S9 samples were separated on Nu-Page 4-12% Bis-Tris 
gel purchased from (Invitrogen/UK) at 200 V for approximately 45 min. The loading capacity 
for each well for S9 and non-S9 samples were 20-30µg/well and 20µg/well respectively. One 
of the difficulties faced during this step was determining the concentration of S9 and non S9 
samples to be loaded onto the SDS gel. This experimental part was repeated many times until 
good protein separation of both skin fractions was obtained. Following staining with 
Coomassie blue to visualize the protein bands, the gels were cut into 2-4 mm and each piece 
subjected to in situ trypsin digestion using method described by (Zhu et al., 2008a).  S9 and 
non-S9 gel pieces were incubated with 0.5-1ml of 25mM Ambic 50% methanol at 37 °C for 
30 min. The process was repeated until the blue dye washed off. The destined gel was washed 
with 0.5-1 ml distilled water. The gel pieces were dehydrated using 1 ml 100 % (Acetonitrile) 
for 15 min. Separated proteins were incubated with trypsin (1 ng/μl) at 37 °C for 16 h until 
complete digestion. The extracted proteins were aspirated and stored at -80 ˚C for nano-
capillary LC-MS/MS analysis. 
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2.2.4. Mass Spectrometry analysis (performed at Health Protection Agency London) 
 
Tryptic peptide mixtures from in-gel trypsin digestion were separated using nanoflow 
reversed phase liquid chromatography and analysed using tandem mass spectrometry (nLC-
MS/MS) on an Ultimate™ 3000Dionex nano/capillary HPLC system (Thermo Scientific 
Dionex™) coupled online to a LTQ OrbitrapTM mass spectrometer (Thermo Scientific). 
 
For peptide separation, buffer A (98/2 water/CH3CN containing 0.1% formic acid) and buffer 
B (10/90 water/acetonitrile containing 0.1% formic acid) were used as mobile phases for 
gradient. Peptide mixtures (10 μl) were first trapped and desalted on a reversed phase trap 
column (Acclaim PepMap100, 300µm i.d. x 5mm, C18, 5µm, 100Å, Thermo Scientific) 
using Buffer A at a flow rate of 25 μl/min and further separated on an C18 reversed-phase 
nanocolumn (Acclaim PepMap100, 75 μmi.d. × 15 cm, C18, 3 μm, 100 Å, Thermo 
Scientific) at 35°C. Separation was achieved using a 45-minute gradient: from 10% to 45% 
solvent B over 45 min, followed by 45% to 90% solvent B over 0.5 min, maintained at 90% 
B for an additional 5 min, then returned to 10% B over 0.5 min at a flow rate of 300 nl/min. 
The total run time was 60 min. 
 
MS/MS data were acquired on the LTQ Orbitrap mass spectrometer controlled by XcaliburTM 
(version 2.1.0, Thermo Scientific). The instrument was operated in positive ion mode and a 
data-dependent ‘top 6’ method was used. MS1 survey scans (m/z 440–2000) were acquired in 
the Orbitrap with a resolution R= 60,000 at m/z 400. The six most abundant multiply charged 
precursor ions detected in the preceding survey scan were selected for MS/MS using 
collision-induced dissociation (CID) with detection of fragment ions in the linear ion trap. 
General mass spectrometric conditions were set as follows: spray voltage at 1.6 kV, capillary 
voltage at 38 V, capillary temperature at 200°C, tube lens at 125 V. Helium was used as 
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collision gas but no sheath or auxiliary gas were applied. CID normalised collision energy 
was set to 35%, activation of q = 0.25, and activation time of 30 ms. The lock mass option 
was enabled using the polydimethyl-cyclosiloxane ion generated in the electrospray process 
from ambient air, protonated (Si(CH3)2O)6 at m/z 445.120025, was used for internal 
calibration in real time to enable accurate mass measurement (method previously used and 
described by Mirza and Gaulton, 2015).   
  
2.2.5. Database searching (performed at Health Protection Agency London) 
MS data were generated in the form of RAW files (Thermo Finnigan file formats), which 
contain all the spectra detected from the LC-MS/MS analysis for each sample. Spectra 
acquired were searched against the non-redundant Swiss-Prot protein database using 
Proteome DiscovererTM(Version 1.4, Thermo Scientific). The search parameters used were: 
Enzyme: trypsin; Fixed (or static) Modifications: carbamidomethylation of cysteine; Variable 
Modifications: oxidation of methionine; Missed Cleavage Sites: 2; peptide mass tolerance ± 
10 ppm. The search results were filtered using Scaffold (Version 4, Proteome Software, 
USA) to minimize the number of false positives, as indicated by a false discovery rate of < 2 
%. Protein identifications were accepted with at least 1 identified peptide (method previously 
described by Ru et al., 2006).  
2.2.6. Uniprot analysis (performed at University of Bedfordshire) 
Genes were identified based on the obtained proteins by MASCOT searching cross-
referenced with Uniprot identifier using the open access Protein Identifier Cross Reference 
Tool (http://www.ebi.ac.uk/Tools/picr/) with search limited to human proteins and mapped to 
Swiss-Prot and TrEMBL database ( method previously used by Parkinson et al.,2014. 
 
41 
 
2.2.7. Gene Ontology analysis (performed at University of Bedfordshire) 
Uniprot identified proteins from the GeLc-MS/MS analysis were submitted into Gene 
ontology Go Term Mapper (http.//go.princeton.edu/cgi-bin/GoTermMapper) and were 
searched against the goa_human (GOA GO slim) and the goa_human(Generic GO slim), for 
cellular compartment and biological process (method previously used by Parkinson et 
al.,2014). 
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2.3. Results 
 
2.3.1. Characterisation of human skin proteome 
Eight human skin samples were analysed for whole skin proteome. Proteomic analysis 
was performed on both S9 and Non S9 fractions. Schematic overview of the gel digestion 
procedure and the S9 and non S9 protein separation are represented on Figure 8. 
Mol. Marker       S9(x8)   NS9(x8)                                 S9                NS9
kDa
x8 samples LC-MS/MS
Data
cut
350
280
180
130
100
70
50 
40
10
Figure8. Schematic overview of S9 and NS9 sample analysis by GeLC-MS/MS method 
 
Proteins of the human skin samples were separated by SDS –PAGE gel and subjected 
to LC-MS/MS analysis, which led to the identification of 1491 tryptic peptides in total, 
corresponding to 260 proteins in total (row data available in appendix table 6). The results 
were analysed based on the presence of at least 2 peptides in all 8 human skin samples.  The 
received data were further refined by selecting the proteins with the same tryptic peptides 
identified across all 8 human skin samples for S9 fractions and based on the presence of ≥ 7 
tryptic peptides identified across all 8 human skin samples for non S9 fractions (row data 
available in appendix table 6). As a result total of 260 proteins corresponding for S9 and non 
S9 fractions were further considered for analysis.  
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The identified proteins in both fractions were compared with Gene Ontology (GO) in terms 
of cellular compartments (Figure 9). 
 
 
Figure 9. Cellular location of proteins identified in the soluble and insoluble fractions was annotated to 
the GOA human GO Slim terms and Generic human GO slim terms for cellular compartment, using 
GO Term Mapper (http://go.princeton.edu/cgi-bin/GOTermMapper) 
 
 
Of the 260 proteins identified, 142 and 118 proteins were determined from the soluble 
(cytosol and microsome) and insoluble (membrane, nuclei etc.) fractions respectively. The 
revealed proteins have diverse physico-chemical properties, with 105 and 82 found 
exclusively in the soluble (cytosol and microsome) and insoluble (membrane, nuclei etc.) 
fractions respectively.  
 
The skin proteome appears to contain components involved in a number of different 
biological processes, including regulation, transport and metabolism etc. (Figure 10).  
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Figure 10 Biological function of all proteins identified from mass spectrometry analysis of human skin. Proteins 
were annotated with the GOA human Go slim terms for biological process, using GO term Mapper 
(http://go.princeton.edu/cgi-bin/GOTermMapper). 
 
 
The identification and quantitative expression level of the proteins, as two examples, 
are represented in Table 1, which estimates relative level of the protein to the most abundant 
protein (considered as 100 %) in the S9 and Non S9 fraction respectively. Each protein level 
was calculated as an average of its peptide levels quantification, analysed by the Thermo 
Protein Centre software (From data set to meaningful biology, 2017) . The calculated 
averages peptide levels of each protein grouped the proteins of the analysed 8 human skin 
samples in order based on their abundance, from highest to lowest. Table 1 displays the most 
abundant proteins in S9 and non S9 fractions based on the calculated average peptide level in 
each one of them (raw data table 6, available in the supplement data).  
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Table 1. Identification and quantitative expression overview of the top ten most abundant proteins identified in 
S9 &NS9 fractions, based on the presence of tryptic peptides in all 8 donors and based on the presence of of ≥ 
2different tryptic peptides identified in all the 8 donors, respectively. 
S9 fraction proteins 
Numbers 
of Peptides 
identified 
MW 
(Da) 
NCBI 
identification 
Relative 
abundance 
(%) 
Keratin, type II cytoskeletal 2 epidermal  18 65,433 NP_000414.2 100 
Histone H4  6 11,269 NP_778224.1 97 
IG gamma-1 chain C region  6 36,105 PT0368 60 
Glyceraldehyde-3-phosphate 
dehydrogenase  3 36,053 CAA25833.1 45 
IG kappa chain C region  3 11,608 P01834.1 42 
Histone H2B type 1-N  4 13,950 NP_003511.1 42 
Keratin, type II cytoskeletal 1  17 66,040 NP_006112.3 38 
Hemoglobin subunit beta  2 15,998 NP_000509.1 37 
Serum albumin  24 69,366 NP_000468.1 36 
IG alpha-1 chain C region  2 37,754 B45874 28 
 
Non S9 proteins 
Numbers of 
Peptides 
identified 
MW 
(Da) 
NCBI 
identification 
Relative 
abundance 
(%) 
Histone H4 type VIII  4 11439 NP_778224  100 
Galectin-7  3 15074 NP_002298  67 
Keratin, type II cytoskeletal 2 epidermal  15 45000 NP_000414.2 65 
ATP synthase subunit beta, 
mitochondrial  2 137923 NP_001677.2 59 
Keratin, type II cytoskeletal 1  17 66040 NP_006112.3 53 
Keratin, type I cytoskeletal 10  20 58828 NP_000412.3 52 
Annexin A2  20 38606 AAH68065.1 43 
Desmoglein-3  4 113748 NP_001935.2 30 
Desmoglein-1  14 99970 NP_001933.2 27 
Fatty aldehyde dehydrogenase 6 54849.8 NP_00102697.
1 
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All the identified 260 proteins were put into toxicological pathway context analysis by 
using ToxProfiler with the WikiPathways and Biocarta database as references (Table 2). 
 
 
 
 
 
 
 
 
46 
 
Table 2 Toxicological pathways in which the proteins from S9 and Non S9 fractions are involved, and identified 
by the ToxProfiler software using WikiPathways and Biocarta databases as reference. 
 
NCBI No S9 proteins Pathway 
NP_001211.3 Beta chain associated protein kinase inflammatory response 
NP_476508.2 collagen type 3 inflammatory response 
NP_000085.1 Collagen alpha inflammatory response 
NP_036246.1 Caspase 1 IL-1 signaling 
NP_001185798.1 Calpain-1 catalytic subunit  IL-1 signaling  
NP_031381.2 Heatshock protein 90 IL-6 signaling  
NP_003861.1 Ras protein activator  Il-4 signaling  
NP_112598.3 Epiplakin EGFR1 Signaling  
NP_000840.2 Glutathione transferase KEAP 1-NRF2  
NP_001743.1 Catalase oxidative stress 
AAF87085.1 Thioredoxine oxidative stress 
 
 
 
 
 
 
NCBI No Non S9 proteins Pathway 
NP_008839.2 Ras-related C3 botulinum toxin substrate 1  Wnt Signalling  
NP_000691.1 Annexin A1  
Prostaglandin Synthesis and Regulation 
NP_001145.1 Annexin A5  
Prostaglandin Synthesis and Regulation 
NP_001144.1 Annexin A4  
Prostaglandin Synthesis and Regulation 
AAH68065.1 Annexin A2  
Prostaglandin Synthesis and Regulation 
NP_001265853.1 Annexin A8-like protein 2  
Prostaglandin Synthesis and Regulation 
NP_112598.3 Epiplakin 
EGFR1 Signaling  
 
ADZ75461.1 Epidermal growth factor receptor  EGFR1 Signaling  
P30453.1 
HLA class I histocompatibility antigen, A-
34 alpha chain   Cytokines and inflammation response 
ADZ75461.1 Epidermal growth factor receptor  
Regulation of Actin cytoskeleton 
NP_005337.2 Heat shock 70 kDa protein 1A/1B  MAPK Signalling  
NP_054768.2 
Acyl-CoA dehydrogenase family member 
9, mitochondrial 
Fatty acid beta oxidation 
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2.4. Discussion 
2.4.1. Characterisation of human skin proteome 
The skin has the ability to grow, renew and differentiate throughout life, providing a  
physical barrier to the environment which limits the inward and outward passage of water, 
electrolytes and various substances, while providing protection against microorganisms, 
ultraviolet radiation, toxicological agents and mechanical injuries. Despite these crucial roles, 
relatively little is known about the global protein composition of skin and how it changes in 
response to exposure to stimuli (Bensouilah et al., 2006).  
The proteins of the S9 and Non S9 fraction in each of the analysed 8 human samples 
were separated using the well-known SDS PAGE electrophoresis. SDS PAGE electrophoresis 
is a powerful technique to separate proteins based on their size using a porous gel matrix. To 
enhance the separation technique and maximise the number of identified proteins, the 
SDSPAGE electrophoresis of the S9 and non-S9 fraction was repeated several times using 
gels with various pour sizes. In the experiment a gel matrix with  pore size from 4 to 12 % 
Bis-Tris gel was purchased from (Invitrogen/UK). The use of a gel matrix with pore size from 
4 to 12% facilitated the separation of proteins with different sizes using the same gel. SDS 
PAGE electrophoresis is a powerful technique, as it relies on the full solubilisation of the 
proteins by SDS (sodium dodecyl sulphate), high tolerance to salts, buffers and detergents and 
consistent digestion by trypsin. The electrophoresis removes from the protein extracts buffers, salts 
and detergents from the protein extracts that may interfere with the mass spectrometry. As a 
result of the trypsinisation, all the tryptic peptides remain in a single fraction. Coomassie blue 
stain, used to visualise the separated proteins, provides quality control prior to the in-gel 
digestion (Piersma et al.,2013). The separation of the proteins in the non-S9 fraction was a 
challenging process. Initially the separation of the proteins in the non-S9 fraction relied on 
their solubility in SDS, however the resulted SDSP PAGE gel electrophoresis did not provide 
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good protein separation. The solubility of the non-S9 fractions was improved by the use of 
9M Urea/2 % Chaps. The collected supernatant was used to determine the protein 
concentration using a BCA assay, followed by SDSPAGE electrophoresis.  The established 
GeLC-MS/MS identified 260 proteins with a broad range of molecular weights and biological 
functions. The study by Taverna and co-workers was focused on the use of LC-MS/MS for 
detection and definition of protein signature in normal human epidermis and dermis by 
MALDI-MS profiling and MALDI-MS imagining respectively by discrete location based on 
histology. The experiment determined the protein differences between epidermis and dermis 
and the slight differences between the papillary and reticular dermis. Furthermore, it 
identified proteins unique to human skin, as well as those associated with unique markers of 
individual variability (Taverna et al., 2011). On the other hand, van Eijl and co-workers used 
the proteomic profiling approach to successfully elucidate enzymes responsible for drug 
metabolism in human skin microsomes and cytosols by utilising the GeLC-MS/MS 
methodology (van Eijl, 2012). 
In the current research the GeLC-MS/MS was applied to the analysis of both S9 and 
non-S9 fractions, leading to the identification of whole human skin proteins with diverse 
biological functions, sub-cellular locations and involvement of toxicological pathways at 
cellular and molecular levels. 
Several Annexin proteins were discovered in both the S9 and non-S9 fractions such as 
annexin 1,2,4,5 and 7, which was proved to be over-expressed in the presence of 
glucocorticoids such as cortisol which inhibits inflammation (Busheri, et al., 2002). Members 
of the Heatshock proteins 70, 90 were identified, their expression was  previously found to be 
altered by cysteine binding skin sensitisers (Natash, 2010).  The heat shock protein-90 family 
is known to protect tissues from various environmental insults and participate in repairing 
damaged tissues (Jayaprakash et al., 2015).  
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Epidermal adhesion is mediated primarily by integrin-associated proteins. Numerous 
in vitro reports have implicated the involvement of those proteins in the regulation of a 
plethora of cellular processes other than adhesion, such as signal transduction, re-
epithelialisation during wound healing, hair growth, and stem cell maintenance. A study of 
the epidermal growth factor suggested that human-like epidermal growth factor protein could 
improve visible signs of photo damage and aging in facial skin (Schouset et al., 2012). 
Mutations to the gene which encodes desmoplakin have been proved to be linked with skin 
defects, the expression of which in turn is regulated by the involvement of cellular pathways, 
and which can be targeted (Pigors, et al 2014).  
Several 14-3-3 family proteins were identified that regulate diverse cellular processes 
by binding to proteins with numerous functions. It has been shown that the 14-3-3 protein is 
over-expressed in a number of skin diseases such as psoriasis, condylomata acuminata and 
actinic keratosis (Lodaygin et al., 2003). A protease such as caspase 14 was identified to be 
involved in filaggrin processing and activated during keratinocyte cornification. Caspase 14 
is mainly involved in inflammation and apoptosis, and plays an important role in the correct 
degradation of (pro) filaggrin and the formation of the epidermal barrier (Deneker et al. 
2009). Thioredoxins are antioxidant enzymes that play important roles in many health-related 
cellular processes by facilitating the reduction of other proteins. Van der Veen and co-
workers demonstrated that the protein is under control of the ARE/EpER element and up-
regulated after its subsequent treatment with cysteine-binding electrophiles (skin sensitiser) 
(Collet and Messens, 2010; Van der Veen et al., 2012). 
The calculated relative abundance of each protein per fraction in Table 1 shows that 
the highest abundance percentage  belongs to Keratin type 2 cytoskeleton and Histone H4 
protein in the S9 fraction, where as the highest proportion from the non-S9 fraction belongs 
to Histone H4. The proteins identified at relatively high proportions can be further analyzed 
50 
 
through their physico-chemical properties and used as model proteins in the ongoing in 
chemico approaches of replacing the current animal models for assessing skin chemicals. 
The proteins identified by GeLC-MS/MS and analysed through ToxProfiler, showed 
that proteins from both fractions (S9 and non-S9) are involved in various toxicological 
pathways such as inflammation, IL-1/4/6- signalling, KEAP 1-NRF2, oxidative stress, 
EGFR1 signalling, MAPK signalling, prostaglandin synthesis and regulation (Table 2). These 
findings may lead to further in-depth studies of those proteins and target them in vitro as 
specific ‘’sensors-markers’’ at specific toxicological endpoints (Natsch, 2010).  
There is continuously increasing demand for the screening of chemicals used in 
cosmetics and personal care products. Research projects are carried out and focused on 
studying the transcriptomes and proteomes as a result of skin allergy with the ultimate aim of 
filling the knowledge gaps in the topic. 
The data and information obtained from skin protein profiling can be further extended 
to quantify reversible post-translational modification of the proteins, e.g. phosphorylation as 
well as irreversible modification such haptenisation. The data can also be used to deeper 
understanding of the skin proteome. For example, knowledge of the relative abundance of 
proteins allow the design of better strategies for the depletion of common proteins, thereby 
allowing low abundance proteins to be uncovered. 
In addition to the above,  the received data set could provide valuable insight into the 
level of key protein nucleophilic residues that are potential targets for the electrophilic 
chemicals or metabolites, the product of which leads to delayed types of hypersensitivity 
reaction. Information obtained from single protein models (Alekcis et al.,2008) showed that 
chemical modification of proteins occurs in specific microenvironments within the 3D 
protein structure. That is why more efforts need to be focused on the role of the 3D protein 
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configuration in determining the ultimate availability of nucleophilic amino acid side chains 
for reaction with exogenous chemicals in relevant physiological conditions.  
2.4.2. Interaction of different cosmetic products 
Since ancient times people used to mix various organic and inorganic sources to develop and 
enhance the effect of different drugs and cosmetic products. With the advancement of the life 
science, the understanding of the human biology on genomic and proteomic levels  scientists 
have begun to combine chemicals used in different products carefully in order to increase the 
product's efficiency and reduce any possible side effects.  The effect of combining different 
chemicals (ingredients) when developing drugs or cosmetic products has been studied for 
more than a century.   
There are three types of actions as a result of the chemical combination in a product.  
a).  Similar action ( dose/concentration addition)- chemicals have same mechanism of action 
but different potencies. 
b). Dissimilar action known as independent action - chemicals have different mode of action, 
but have no influence on each other. 
Both the similar and dissimilar modes of action are based on the assumption that chemicals in 
the mixtures do not influence each other's toxicity and each has its own biological target. 
c). Different chemical interactions. The interactions can be divided into strong (synergetic, 
potentiating, supra- additive) or weak ( antagonistic, sub-additive, inhibitive, infra- additive). 
The interaction of the chemicals can vary based on the dose, duration of exposure and  the 
biological molecules targeted by those chemicals (Scientific Committee on Health and 
Environmental Risks, 2011) 
The identified skin proteins as a result of the skin proteome characterisation, can be used as 
model proteins to study the effect of the drug combination. Skin samples can be treated with 
individual chemicals followed by a treatment with a combination of two or more chemicals at 
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the same time to monitor any protein modifications and determine the effect of the drug 
combination. It is crucial to highlight few suggestions by Foucquier and Guedj, 2015 when 
studying drug interactions: the design of the analytical methods has to be appropriate for the 
classified drug interaction; A standard framework has to be used when analysing drug 
combinations. The framework has to be clear and targeting the different types of interaction 
and established based on well understood mechanism of drug's action, not based on any 
assumptions  as well as being an easy to perform by other scientists. The analysis has to be 
adapted to the different stages of the research process(discovery, preclinical and clinical 
stages) (Foucquier and Guedj, 2015). 
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Chapter 3 
In chemico approach in studying skin sensitisers 
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3.1. Introduction 
One of the most intensely studied non-animal approaches aiming to substitute in vivo testing 
is the in chemico approach. This approach is based on experimental physicochemical 
measurements of the nucleophilic protein and electrophilic hapten in order to study the 
specificity and correlation between the protein reactivity and chemical potency (Cronin et al., 
2009). 
Studies of the relationship between sensitisation and chemical-protein reactivity have been 
carried out using nucleophile molecules, peptides containing mostly lysine and cysteine, and 
protein models by measuring peptide depletion as a consequence of the protein–hapten 
formation. Residues such as lysine, tyrosine, cysteine, histidine and arginine have been 
proved to be involved in the peptide-haptenisation process leading to skin allergy (Aeby et 
al.,2007) 
Covalent modifications of skin proteins by allergens play a crucial role in the skin sensitising 
process, and a full understanding  of the protein-hapten mechanism and specificity of reaction 
will lead to an improvement in  development of in chemico approaches for testing chemicals 
in cosmetics and personal care products. The current in chemico reactivity assays for 
screening chemicals suggest that a large amount of peptide depletion needs to be recorded in 
order to categorise a chemical as a sensitiser. This leads to performing  in chemico 
experiments using peptide: chemical reactivity in the presence of an excessive amount of 
chemicals. Therefore, the nucleophile (peptide) :electrophile (chemical) ratio used in in 
chemico experiments is of high importance. Roberts and Basketter suggested that an 
important aspect when developing an electrophile-nucleophile reactivity assay is to consider 
whether the tested chemical is pure with no other impurities, or whether it is impure with a 
combination with other chemicals that could present as a trace or in higher quantities. If the 
tested chemical sample is impure, then the reactivity assay has to be developed with an 
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excess of the sample, because if the chemical of interest is unreactive a significant 
nucleophilic depletion will still be observed.  If the tested chemical is a pure substance, an 
excess of the nucleophile has to be used, so any trace impurity in the sample will not interfere 
with the final results and cause confusion (Roberts and Basketter, 2009; Pease et al., 2010). 
 Studies of the relationship between sensitising potency and chemical-peptide reactivity have 
been carried out using peptides containing mostly lysine and cysteine or model proteins 
(further trypsinised to peptides), followed by measuring peptide depletion by using HPLC, 
UV spectrometry and mass spectrometry (Aeby et al., 2007; Jeonge et al 2013). Due to the 
lack of knowledge in terms of the skin proteome, and which proteins exactly can be targeted 
by the sensitisers, the current investigations using in chemico approaches are mostly based on 
the use of model nucleophiles, synthetic peptides and recombinant proteins (Aleksic et al., 
2008) 
Although all chemicals with reactive electrophiles will form a covalent adduct with 
nucleophilic proteins, the mechanism of action is different for different chemicals, therefore it 
can be used to distinguish between the strength and the type of many chemicals (Chipinda et 
al.,2011).  
The in chemico approaches are simple to perform and easy to based on the incubation of 
peptides and model proteins with different chemicals at different times and temperatures. This will 
help to determine the nucleophile reactivity and the study of the protein-chemical mechanism 
of interaction. In chemico approaches are practical and the chemical reactivity can be 
explained by established facts in organic chemistry. 
 A major drawback of in chemico approaches is the dissimilarity between the behaviour of the 
protein in a real system and during the experiment. During in chemico, the proteins are 
considered as separate biomolecules with no consideration of the surrounding real systems 
(bioavailability of the skin, water solubility, metabolic transformation and immune 
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recognition). Very often (another source of error) the proteins may be modified by the non- 
physiological conditions of the experiment (Astoriol and Worth, 2011).  
The in chemico approaches can be used as a tool along with other in vitro methods to build up 
a full understanding of the electrophile-nucleophile interaction and hence contribute to the 
total replacement of the current in vivo assessments on the various chemicals used in 
cosmetics and personal care products (Chapin et al., 2013). 
 Many studies have started focusing and studying the correlation between the reactivity of 
proteins and chemical potency using recombinant proteins.  
A study by Aleksic et al., 2007 using Human Serum Albumin (HSA) incubated with different 
chemicals: strong sensitizer, moderate, irritant and non-sensitizer led to very promising 
results. The samples were further analysed by HPLC/MS, showing that the amino acids 
lysine, histidine, tyrosine and cysteine were modified by both strong and moderate 
sensitizers, whereas HSA treated with irritant and non-sensitisers did not show any protein 
modification under any conditions. The results suggested the in chemico approach can be 
used to distinguish between sensitizers and non-sensitizers (Aleksic et al., 2007). 
Maja Aleksic and co-workers further extended their investigation and worked on two more 
protein models, i.e. Cytokeratine 14 (K14) and Cofilin, using sensitizers with different 
potency: strong, irritant and non-sensitisers (DNCB, BC and DCNB). The samples were 
further analysed by MALDI/MS and Nano-LC/MS/MS, and as a result protein depletion was 
not detected on the proteins treated both with non-sensitizers and with irritant chemicals. The 
study has also proved that the reactive chemicals target the nucleophilic amino acids residing 
in specific microenvironments of the 3D protein structure (Aleksic et al., 2008) 
The current study is performed to investigate nucleophile reactivity using model recombinant 
protein Apomyglobin with sensitisers of different potencies,  aiming to develop an 
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understanding of the mechanism of protein-hapten formation and to find any specific binding 
locations, considering different doses and time incubation.  
Apomyglobin (APG) MW16951 is a protein synthesised in the Endoplasmic reticulum (ER), 
this protein is  able to bind to the heme on the mitochondrial outer membrane to form 
holomyglobin, which keeps and transports oxygen into muscle tissues. The ApoMb structure 
is highly helical and its hydrophobic core is tightly packed (Basova et al., 2004) 
Top down Mass Spectrometry is a novel technique of measuring intact protein. It is a 
measuring tool based on the mass/charge ratio (m/z) of charged molecules which pass 
through an electric and magnetic field. The Top Down MS gives us detailed information 
about the presence of a particular protein as well as its amino acid composition and any post-
translational modification (e.g. phosphorylation of the protein). The Top Down approach 
differs from the already available MS techniques, as it is possible to measure molecules with 
high molecular weight without those molecules requiring previous proteolytic digestion, and 
hence it measures the mass/charge ratio of the intact protein-chemical adduct. In addition, 
Top Down MS also provides high resolution and accuracy in presenting the results data 
(Kellie et al., 2010). 
Top-down MS techniques are increasingly being applied for high-throughput protein 
analysis, in particular to characterise more complicated combinations of intact protein-
chemical interactions (Kelleher et al., 2004; Kellie et al., 2010), with the clear advantage that 
the quantification of multiple protein forms with combinations of chemicals is straightforward 
when the mixture is measured intact. This new technology applied in this project (with 
collaboration with Health Protection Agency, England) may provide crucial information about 
the haptenisation pathways.  
The aim of the experiment is to apply the novel technique of Top Down MS with higher 
resolution and accuracy, in order to measure protein depletion as a result of the protein-
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hapten adduct formation with the purpose of elucidating the mechanism of protein-hapten 
formation and studying any specific binding between sensitisers and model proteins. 
 
3.2. Materials and Methods 
3.2.1. In chemico experiment 
 Apomyglobin(APG) protein (MW 16.5 kDa, Sigma Aldrich, UK) as a lyophilised powder 
was dissolved in Tris buffer at a working solution of 10µg/µl. The effective nucleophile: 
electrophile molar ratio of APG:chemical is 1:2.5, which was calculated based on the number 
of nucleophile side chains of APG. Initially APG was incubated with four chemicals with 
different potency: 2-4-Dinitrochlorobenzene (DNCB) (potency: strong); Phenyl Salicylate (PS) 
(moderate), Benzaldehyde(BZ) (a non-sensitiser) and BenzalKonium Chloride (BC) (an 
irritant). Samples were prepared by mixing protein and chemical in the following ratios: 
1:500, 1:100, 1:50, 1:2.5, 10:1 and 100:1, and incubated at 18 ̊C for 24h, 3 days, 7 days and 
15 days, separately. Subsequently, 21 chemicals with known skin sensitising potency from 
the LLNA database with name and class defined by LLNA were selected (Table 3). Samples 
were prepared at a 1:500 protein:chemical ratio. The samples were incubated at 18 ̊C for 24 
hours. In addition to the above, one of the samples treated with DNCB, and the control were 
incubated at 32 ̊C and 37°C in order to replicate the skin and body physiological conditions 
respectively. Control samples were prepared by using acetone/water in buffer containing 
same amount of the protein. 
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Table 3 List of chemicals tested in the in chemico experiment 
No Chemicals Class (LLNA) 
1 Maleic acid (MA) False-positive (Irritant) 
2 Sodium Dodecyl Sulphate (SDS) False-positive (Irritant) 
3 Benzalkonium chloride (BC) False-positive (Irritant) 
4 Chlorobenzene (CB) Non-sensitiser 
5 Methyl salicylate (MS) Non-sensitiser 
6 Benzaldehyde (BZ) Non-sensitiser 
7 Coumarin (CM) Non-sensitiser 
8 Ethyl acrylate (EA) Weak sensitiser 
9 Methyl methacrylate (MM) Weak sensitiser 
10 Eugenol (EG) Weak sensitiser 
11 2,4-dichloronitrobenzene (DCNB) Weak sensitiser 
12 2-Mercaptobenzothiazole (MB) Moderate sensitiser 
13 Diethyl Maleate (DM) Moderate sensitiser 
14 Dihydrocoumarin (DC) Moderate sensitiser 
15 Phenyl Salicylate (PS) Moderate sensitiser 
16 2-4-Dinitrochlorobenzene  (DNCB) Strong sensitiser 
17 Dibenzoyl peroxide (DP) Strong sensitiser 
18 p-Benzoquinone (BZ) Strong sensitiser 
19 p-Phenylenediamine (PD) Strong sensitiser 
20 Isoeugenol (IE) Strong sensitiser 
21 Formaldehyde (FA) Strong sensitiser 
 
 
 
3.2.2. Top-down Analysis (Health Protection Agency London) 
Online chromatography was performed with the Thermo Easy nLC 1000 ultra-high pressure 
HPLC system (Thermo Fisher Scientific) coupled online to the Q Exactive (Thermo 
Scientific). The instrument was controlled by Xcalibur (Q Exactive Plus 2.3, Thermo 
Scientific).  
For chromatographic separation, buffer A (water containing 0.1% formic acid) and buffer B 
(acetonitrile containing 0,1% formic acid) were used as mobile phases for gradient 
separation. 2 μl of samples (diluted in water/acetonitrile (1:1, v:v) were loaded into a reversed 
phase Nano Trap Column (Acclaim PepMap 100, 100µm i.d. x 2cm, C18, 5µm, 100 Å) and 
further separated on an C18 reversed-phase nanocolumn (Acclaim PepMap100, 75 μm i.d. × 
15 cm, C18, 3 μm, 100 Å, 75 μm i.d. × 15 cm, Thermo Scientific) with a linear gradient of 4-
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65% buffer B at a flow rate of 300 nL/min over 12 min. Due to loading, lead-in and washing 
steps, the total time for an nLC-MS/MS run was 21 min.  
For top down data acquisition, the instrument was operated in positive ion mode and a data-
dependent ‘top 4’ method was used. Survey scans (400 – 2000) were acquired at a resolution 
of 70,000 at m/z 200 with maximum IIT of 100 ms. MS/MS was performed by HCD 
fragmentation using CID. Resolution for HCD spectra was set to 17,500 at m/z 200 with 
maximum IIT of 50 ms. Normalized collision energy was set as 20. The ‘underfill ratio’, 
specifying the minimum percentage of the target ion value likely to be reached at maximum 
fill time was defined as 1.0 %. Charge exclusions of unassigned and 1 – 3 were selected, in 
order to exclude precursor ions with 1 - 3 and unassigned charge states from fragmentation 
selection. A Default dynamic exclusion of 15.0 s was selected to prevent an ion from 
triggering a subsequent data-dependent scan after having already triggered a data-dependent 
scan. Furthermore, the S-lens RF level was set at 70, which gave optimal transmission of the 
m/z region occupied by intact proteins.  
Top down data were processed and analysed using Xcalibur (Q Exactive Plus 2.3, Thermo 
Scientific).  
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3.3. Results 
3.3.1. Top-down mass spectrometry 
 
APG was incubated at 18 °C for 24 h with 2,4-dinitrochlorobenzene (DNCB), as a 
strong sensitiser, which has been used as a model hapten in a number of studies. The data 
received from top down MS (Figure 11) shows a clear shift of the m/z ratio towards 8.74 m/z 
(=166.06 MW), i.e. towards higher values of the intact protein-hapten conjugate in 
comparison with the chemically untreated APG sample (control). The highest peak on the 
DNCB-treated sample corresponds to 901.85 (z=19) (Figure 11 B), whereas on the control 
sample (untreated), the highest peak is 893.11 (z=19) (Figure 11 A). Subtracting 893.11 from 
901.85 gives a shift of 8.74m/z shift. This shift suggests that the difference in molecular 
weight between control and treated sample is ≈166.06 MW. This can be explained by 
nucleophilic substitution on the DNCB aromatic ring with the loss of chlorine atom.  The 
shift of m/z ratio towards higher values corresponds exactly with the mass addition of the 
reacted DNCB chemical molecule (with chlorine atom excluded), as a result of the formation 
of a protein-hapten adduct . 
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Figure 11. MS spectrum of APG-DNCB sample. A:control (APG alone + vehicle); B: APG modified by DNCB  
incubated at 18 °C (mass shift of 8.74m/z ≈166.06 Da).  
 
 
B 
A 
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Figure12. MS spectrum of APG-DNCB sample. A:control (APG alone + vehicle); B: APG modified by DNCB  
incubated at 18 °C (mass shift of 7.64m/z ≈168.08 Da); C. APG modified by DNCB  incubated at 32 °C shows 
two peaks : The first peak with a mass shift of  7.64 m/z ≈168.06. The second peak with a mass shift of  15.14 
m/z. The 15.14 m/z ≈333.08. 
 
 
APG was incubated with a strong sensitiser (DNCB) at 32° C (skin physiological 
condition) for 24h. The experiment was repeated at 18 °C and 32°C for comparison analysis. 
The received mass spectra (Figure 12) at 18°C show a clear shift in the mass spectrum, 
corresponding to an m/z ratio of 7.64 m/z ratio ≈168.06 MW between the control (untreated) 
APG sample and the treated one. At 32°C the mass spectrum shows two shifts (two peaks): 
one corresponding to 7.64 m/z (≈168.06 MW) and an additional peak corresponding to 15.14 
m/z (≈333.08 MW) (Figure 12). The two shifts suggest that most probably two DNCB 
molecules are bound to the APG molecule. 
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Analysis of the time and dose courses of DNCB interacting with APG is still ongoing, together with 
the outcomes from 21 other chemicals incubated with the protein. 
 
 
 
3.4. Discussion 
 
3.4.1. In chemico approach by Top-down mass spectrometry 
 
In the current experiment, the new top-down MS technique developed at HPA was 
applied. Top-down MS is a novel technique for measuring intact proteins, providing detailed 
information about the interaction between protein and ligand as well as post-translational 
modifications (Compton and Kelleher, 2012; Rose et al., 2012). The current experiment gave 
encouraging results which promised to distinguish between sensitisers and non-sensitisers, 
shown by a clear shift of the m/z ratio towards higher values where the APG protein was 
treated with a strong sensitiser chemical (DNCB) (Figure 11)The control sample incubated at 
18ᵒC shows a peak at 893.11 (z=19) as the most abundant molecule. The peak at the control 
sample corresponds exactly to the mass of the APG (893.11 x 19 ≈ 16969Da). The APG 
chemically treated with DNCB 18°C shows a peak at 901.85 (z=19) as the most abundant 
molecule. The peak at the treated sample corresponds to a mass higher than the mass of APG 
(901.85 x 19 ≈ 17135.15 MW).  This shift in the m/z ratio can be explained based on the 
physicochemical properties of APG and DNCB, as well as established facts in organic 
chemistry. The m/z shift ratio (Figure 11) corresponds to an m/z ratio of 8.74 (901.85-893.11 
= 8.74), which, converted to mass, gives 166.06 MW (8.74 x 19). The molecular mass of 
DNCB is 202.65 MW, hence the increase in the mass of the treated sample  corresponds to the 
addition of a DNCB molecule (202.65 MW) to the mass of APG, with a loss of 35 MW 
(202.65 - 166.06 ≈ 35), which corresponds to the mass of a single chlorine atom (Figure 13).  
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Figure 13. Predictive diagram of the DNCB-apomlyoglobin adduct formation following the incubation 
of apomyoglobin with extreme sensitiser (DNCB) at 18 °C for 24 h. The change of the mass as a result of the 
incubation with DNCB suggests that the protein-hapten conjugate formation is  based on the addition of the 
DNCB molecule to a single location  on the amopyoglobin protein (masses calculated based on the mass 
spectrometry data) with the loss of a single chlorine.  
 
 
The experiment was repeated at 18°C and 32°C (skin physiological condition).  The 
incubated control sample shows a peak at 771.458 (z=22) as the most abundant molecule. The 
peak at the control sample corresponds exactly to the mass of APG (771.458 x 22 ≈ 16972 
MW). APG chemically treated with DNCB at 18 ᵒC shows a peak at 779.098 (z=22) as the 
most abundant molecule. The peak at the treated sample corresponds to a higher mass than the 
mass of APG the mass of APG (779.098 x 22 ≈ 17140.156 MW).  This shift in the m/z ratio 
can be explained based on the physicochemical properties of the APG and DNCB as well as 
the knowledge of the organic chemistry. The shift in the m/z ratio (Figures 12 A and B) 
corresponds to (779.098- 771.458 ≈ 7.64)  7.64 m/z, and ratio converted to mass gives 168.08 
MW (7.64 x 22). The molecular mass of DNCB is 202.65 MW, hence the increase in the mass 
corresponds to the addition of a DNCB molecule to the APG  (202.65 MW) with a loss of 35 
MW (202.65 - 168.08 ≈ 35), which corresponds to the mass of a single chlorine.  
APG chemically treated with DNCB at 32° C shows two peaks: one at 779.053 (z=22) 
and another one at a higher shift corresponding to 786.598 (z=22). The first peak can be 
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explained with a mass shift equal to 7.59 m/z (779.053 - 771.458), which, converted to 
molecular weight, gives 7.59 x 22 = 166.98  MW. By subtracting this from the molecular 
weight of DNCB (202.65), a figure of 35 is obtained (202.65-166.98=35); thus it can be 
concluded that a molecule of DNCB is added to APG, with the loss of one chlorine atom. The 
second peak clearly shows a double shift (786.598 - 771.458 ≈ 15.14), 15.14 m/z. The 15.14 
m/z ratio converted to molecular weight corresponds to 333.08 MW (15.14 x 22) (Figures 12 
A and C). The change in the molecular mass corresponds to the addition of two DNCB 
molecules, each with 166.5 MW, and the loss of two chlorines ≈ 72.16 MW (2 x 36.08 MW) 
(Figure 14). 
Interestingly, the new results (Figure 12) have shown more binding sites on APG available to 
by DNCB under  physiological condition (32° C), which can be studied possibly over 
temperature, time or dose course. Further analysis is ongoing,  together with the analysis of 
21 more chemicals with different potencies. 
 
Figure 14. Predictive diagram of DNCB-apomlyoglobin adduct formation following incubation of apomyoglobin 
with extreme sensitiser (DNCB) at 32 °C for 24 h. The change of the mass as a result of chemical incubation 
suggests that protein-hapten conjugate formation is based on the addition of two DNCB molecules to different 
locations on the amopyoglobin protein (masses calculated based on mass spectrometry data) with the loss of two 
chlorines.  
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The sensitisers' reactivity using recombinant proteins as model proteins has been 
studied (Aleksic et al., 2007), in which human serum albumin was incubated with chemicals 
of different potencies followed by MALDI-TOF-MS analysis. The results showed that 
Nucleophile residues, of which the recombinant protein is composed were covalently modified in 
selective ways with different modes of action towards high and moderate sensitisers (DNCB 
and PS respectively) and no reactivity towards non-sensitisers (DCNB) including irritants 
(SDS and BC). The same research group, one year later, used MALDI-TOF-MS analysis to 
investigate the reactivity of two model proteins, Cytokeratine 14 and Cofilin, towards strong 
sensitisers (DNCB), irritants (BC) and non-sensitisers (DCNB). The study showed that reactive 
chemicals targeting nucleophilic amino acids reside in specific microenvironments of the 3D 
protein structure that are conducive to reactivity (Aleksic et al., 2008). Here it is very 
important to highlight that Aleksic and co-workers used the MALDI-TOF-MS technique, in 
which protein was trypsinised into peptides before performing mass spectrometry.  
Information obtained from the single protein model (Aleksic et al.,2008) showed that 
chemical modification of proteins occurs in a specific microenvironment within the 3D 
protein structure. Aleksic and co-workers used Insight II software to prepare computer-based 
images, and to show the location of the DNCB binding, and the number of the modified 
protein amino acid residues. That is why future studies need to be focused on the role of the 
3D protein configuration in determining the ultimate availability of nucleophilic amino acid 
side chains for reaction with exogenous chemicals under relevant physiological conditions.  
Protein Centre is a computer-based software provided by Thermo Scientific as a web-
based interpretational tool which is able to compare proteins data. Protein Centre provides 
comparative information between identified proteins, reveals the biological context of different 
protein data sets, provides protein quantitative analysis and studies protein involvements in 
different biological pathways. The software can be used to compare treated and untreated 
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samples, which makes it a suitable tool to analyse APG, both untreated, and treated with the 21 
chemicals listed in table 3. In this way Protein Centre will not only provide a comparative 
study between treated and untreated samples using MS raw data, but also  will provide a wider 
overview about the characterisation of intact protein(s) (From data set to meaningful biology, 
2017). 
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Chapter 4 
In vitro approach in studying skin sensitisers 
Phase II xenobiotic metabolic enzymes 
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4.1. Introduction  
The metabolic detoxification of xenobiotics is a crucial body function usually performed by 
phase I and phase II enzymes called xenobiotic metabolic enzymes (XMEs). Considering the 
liver as the main metabolising and detoxifying organ in the body, most research activities are 
based on liver xenobiotic enzymes. There is a lack of research when it comes to cell-specific 
metabolic enzymes, in particular in the human skin, considering its important role against 
chemical exposure (Esser and Gotz, 2013). 
Recent studies suggest that chemical-induced changes in the expression of some 
metabolic processes in the skin may be a characteristic of skin sensitisers (Natsch, 2010). 
Despite some research publications that documented mRNA expression of enzymes or 
quantifying enzymatic activity in human or rodent skin (Gotz et al., 2012a & 2012b), very 
little information is available documenting metabolic enzyme expression levels, other than 
that performed by the Cosmetics Europe (formerly COLIPA) skin metabolism initiative. The 
results not only demonstrated equivalent enzymatic activity of various phase I and II metabolising 
enzymes in native or reconstructed 3D human skin (Gotz et al., 2012a & 2012b), but also an 
equivalent expression level of metabolising proteins (van Eijl et al., 2012). However, no work 
on chemical sensitiser-induced expression at molecular levels (mRNA or protein) has been 
undertaken and this key knowledge gap remains (Hewitt et al., 2013).  
The skin protection role does not stop at preventing harmful substances from entering 
the body. Metabolising these chemicals into simpler compounds in order to pump them out of 
the cells is performed mainly by phase I and II xenobiotic metabolic enzymes (XME) 
available in the skin.  
Drug metabolism can be divided into 3 phases. The first phase involves a group of 
XMEs such as cytochrome P450 oxidases, known as XME phase I, which introduce polar or 
reactive groups into the xenobiotic (hapten).  The modified compound then conjugates with 
another polar compound under the catalysis of enzymes such as Glutathione-S-transferases, 
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known as XME phase II. In phase III the xenobiotic conjugate can be further recognised by 
efflux transporters and pumped out of the cells (Ioannides, 2002) (Figure 15).  
R
R         R
O
R-OH
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Electrophiles
Nucleophiles
R=O
(GSH)
Gluthation
conjugate
R-SG
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R-NH2 R-SO3H
R-Ac
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Phase III further metabolism and pump out of the cell
Figure 15. Schematic representation of drug metabolism. Phase I includes oxidation, hydrolysis, reduction. Phase 
II includes the formation of hydrophilic compound R-SG, sulfation, acetylation and formation of acetyl Co-A 
and glucuronidation using glucuronic acid. Phase III involves further metabolism and pump of the product out of 
the cell. 
 
Despite the important role of the XME in detoxification of various xenobiotics, there is a 
surprising lack of research on skin XME. Cosmetics and pharmaceuticals used 
occupationally, accidentally and intentionally, contain chemicals which, in many cases, lead 
to skin irritation, inflammation, allergy and even cancer (Esser and Gotz, 2013). 
The increased interest in studying skin metabolism, especially since the establishment of the 
7th amendment to the European Cosmetic Directive for the replacement of animal models of 
chemical assessment, has led to extensive investigation of the skin as an active metabolising 
organ in many toxicological studies. The whole human skin, especially the keratinocytes in 
the epidermis, proved the presence of both phase I and phase II XME  (Gotz et al. 2012a,b). 
72 
 
COLIPA (European Cosmetic, Toiletry and Perfumery Association) has studied various   
phase I and II XMEsin order to establish the XME profile in the human skin, and compare it 
with developed in vitro skin models. 
In vitro models for assessing skin irritation and toxicity have a number of disadvantages, 
from species-specific metabolism to the ethical issues and risk assessment associated with 
such research. COLIPA has generally worked on two projects. One project focused on 
protein expression of XME in vitro in whole skin, 3D skin models and keratinocytes 
monolayer using a label-free proteomic technique. 
The second project involved measuring the activity of the XME phase I and II in vitro using 
3D skin modes, whole ex-vivo human skin and epidermal keratinocytes. Some XME phase I 
were not detected, or if detected they were at a low level, such as cytochrome P450 
monooxygenases in whole skin. However, XME phase II GST (glutathione-S-transferase), N-
acetyltransferase and UDP glucuronosyl-transferase were detected on mRNA and protein 
level in the whole skin and 3D models at levels similar to those in liver. 
It is important here to highlight that the presence of mRNA which encodes a specific enzyme  
is not a definite indication of the presence of the respective protein or even a measure of its 
activity (Hewitt et al., 2013) 
GST (Glutathione-S-transferase) represents a phase II XME involved in catalysing the 
reaction of glutathione and an electrophilic substrate, hence preventing toxic injuries in many 
tissues. 
Currently much research shows interest in studying the GST enzymes in organs frequently 
exposed to toxic electrophiles such as liver, intestine and skin. 
Despite the importance of the skin as a barrier against toxic chemicals, very little is known 
about the XME in the skin, especially the epidermis. The epidermis is mainly composed of 
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keratinocytes, so they can be used as suitable model for studying XME phase II enzymes 
(Blacker et al., 1991). 
 4.1.1. Regulation of XME phase II- Keap1-Nrf2-ARE 
 The Keap1-Nrf2-ARE pathway is involved in the regulation of the transcription of 
mainly phase II XME. The Keap1-Nrf2-ARE pathway is highly expressed in many cell types, 
including keratinocytes (Esser and Gotz, 2013). 
The Keap1-Nrf2-ARE pathway can be activated by different chemicals (haptens). In an 
uninduced condition, Keap1 is associated with the Nrf2 factor, forming a Keap1-Nrf2 
conjugate. In the presence of a hapten, the Keap1 protein disassociates from the Nrf2 factor, 
where the hapten covalently binds to the cysteine residues of the Keap1 protein.  Human 
Keap1 protein has been proved to contain 25 cysteine residues, however modification of 
some of them can lead to the release of Nrf2 from the Keap1-Nrf2 conjugate. The free Nrf2 
migrates to the nucleus where it binds to the ARE regulatory element and regulates the 
transcription of a series of XME (Figure 16), (Natsch, 2010; Jacquoilleot et al., 2015).   
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Figure 16. Keap1-Nrf2-ARE pathway. Keap1-Nrf2 complex exist in the cytoplasm. When reacting with hapten, 
the Keap1 disassociates from Nrf2, leading to Nrf2 translocate to  the nucleus. In the nucleus Nrf2 forms a 
dimer with Maf protein. The haptenised Nrf2-Maf complex bind to DNA and facilitate to the transcription of the 
target gene (Natsch, 2010). 
 
 
Many researchers have focused on developing new or on improving existing in vitro 
models for testing sensitisers, aiming for complete replacement of animal models with non-
animal models. Regardless of the different approaches used to achieve this goal, their 
common aim is to study changes in the cell-specific response towards potentially different 
chemicals, utilising genomics and/or proteomics techniques, leading to the development of 
alternative techniques for chemical risk assessment. 
 
4.1.2. Glutathione-S-transferase (GST) 
Glutathione-S-transferase (GST) is considered to be one of the most important phase 
II xenobiotic metabolic enzyme given its role in detoxifying allergen, and preventing tissue 
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damage by oxidative stress (Kimura et al., 1998). GST is characterised by its ability to 
conjugate xenobiotics by being activated through small molecular weight organic donor 
molecules such as  glutathione; as a result the allergen is detoxified and eliminated from the 
body. HaCaT cells are known to express higher levels of GST when exposed to varying 
quantities of electrophiles (Jacquoilleot et al.,2015).  
Despite the fact that studying and experimentally monitoring the protein expression 
level and activity are commonly used and considered accurate, studies based on gene 
expression at the mRNA level using advanced qRT PCR still can provide results with high 
sensitivity and reliability (Luu-The et al., 2009).  
The GST xenobiotic metabolic enzyme can exist in five different isoforms: alfa (GST A), mu 
(GST M), theta (GST T), pi (GST P) and Z (GST Z), with GST P being the predominant 
epidermal isoform (Gotz et al., 2012a) 
Studies by Gotz et al., 2012a and Luu-The et al., 2009 investigated the expression of 
GST in reconstructed skin models and in human skin (dermis, epidermis) demonstrated a high 
level of GST P isoform expression in response to potential sensitisers.  
Hewitt et al., 2013 performed a comparison between XME phase I and II protein 
expression and activity across various skin models, cells lines and native skin. As a result, 
GST P protein expression and activity were detected across HaCaT cells, native skin and 
NCTC cells. The same study was extended by looking at the mRNA expression of various 
quantities of XME, including GST P and omega (xenobiotic metabolic enzyme phase II)  
expressed in 3D skin models and HaCaT cells. The mRNA level expression of GST P and 
omega detected in HaCaT cells showed the potential to metabolise a wide spectrum of 
xenobiotics at the same rate as NCTC and NHEK cells. Interestingly, GST alfa and mu were 
detected in native human skin, but they were not detected in HaCaT cells. This had been 
proved earlier by Blacker et al., 1991.  
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The aim of the experiment was to study the regulation by chemicals of the expression 
of phase II XMEs, in order to enhance the understanding of metabolic pathways. The 
research was primarily intended to discover any pattern or consistency in the “induced 
behaviours” of phase II metabolic enzymes in response to chemicals of differing sensitising 
potency and binding mechanisms. 
 
 
4.2. Materials and Methods 
 
4.2.1. Cell recovery and culture:  
 
HaCaT cell line (Cell Line Service, CLS, Germany) was recovered from liquid nitrogen. 
HaCaT cells were cultured in DMEM (Dulbecco's Modified Eagle's medium), supplemented 
with 10% of foetal bovine serum, 1% of penicillin-streptomycin and 2mM L-glutamine at 37 
ºC/ 5% CO2 up to 80 % confluence.  
 
4.2.2.MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay:  
Before the chemical exposure, the cells (5x104cells/100µl) were cultured into each well of a 
96-well plate for 24h. HaCaT cells were then treated with chemicals with different potency 
[2,4-dinitrochlorobenzene (DNCB) (extreme); phthalic anhydride (PA) (strong); 
benzalkonium chloride (BC) (irritant) and benzaldehyde (BZ) (non-sensitiser)] prepared in 
DMSO. For each chemical a range of concentrations (0.01µM; 0.1µM; 1µM; 10µM; 100µM) 
was used to treat the cells for 24h to determine cytotoxicity. Following chemical incubation 
in each well, 25 μl MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] 
solution prepared in sterile PBS (Phosphate buffer saline was added).  The microtitre plate 
was incubated at 37 °C for 2 hours. 100μl of lysing buffer was added to each well and left 
overnight. Absorbance was measured at 590-600 nm using a spectrophotometer (methods 
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described previously by Zhu et al., 2008b). Statistical analysis was performed using Graph 
Pad prism software. Ordinary one way ANOVA non-repeated measures analysis was 
performed on all the concentrations per each chemical used to treat HaCaT cells. The analysis 
then was corrected for multiple comparisons using Tukey's multiple comparison test. 
Maximal 20% death was defined as the criteria of selecting chemical concentrations for 
further analysis.  
 
 
4.2.3. Treating HaCaT cells with the same dose (10μM) of 2,4-Dinitrochlorobenzene (DNCB) 
and Phthalic Anhydride (PA) at different incubation periods   
2,4-Dinitrochlorobenzene (DNCB) and phthalic anhydride (PA) were prepared in DMEM medium at 
10 μM final concentration based on MTT assay. Maximum 20% death is the criterion for choosing 
the above chemical concentration. Control was prepared using sterile DMSO (dimethyl sulfoxide) in 
DMEM medium. HaCaTa  cells were subcultured 5x105 cells/ml in 6 well plates and incubated with 
DNCB and PA over a range of incubation periods 0.5h; 1h; 2h; 3h; 4h; 6h and 24 h at 37 °C, 5% 
CO2. 
 
4.2.4. mRNA extraction and cDNA synthesis 
HaCaT cells treated with DNCB, PA, and the control cells had their mRNA extracted using RNeasy 
MiniKit (Qiagen, Germany). mRNA concentration was determined using NanoDrop T009 
(ThermoScientific, UK) as per manufacturer requirements. 
cDNA was synthesised with a final concentration of 1μg using PCRBIO cDNA Synthesis Kit 
(PCRBiosystem, UK).   
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4.2.5. Primer design: One pair of primers per GST Pi gene and GAPDH gene were designed 
by the NCBI website (http://www.ncbi.nlm.nih.gov). The GSTpi gene accession number was 
entered into the “Enter accession” section on the http://www.ncbi.nlm.nih.gov website. The 
PCR product size was selected to be between 70 and 500 bp. Two of the primers were 
selected based on the generated results and copied into a word document for manual 
annotation. 
 
4.2.6. Qualitative determination of the designed GSTpi primers  
Primers were received in a lyophilized state and the primer pellet was resuspended with PCR water 
to generate 100 μM stock solution, using the information provided on the primers' tubes. Working 
solution 20 μM was generated by dilution the stock solution at a 1:5 with 10mM Tris, pH 8.8. The 
designed primers underwent qualitative analysis on the standard, control and treated samples for 
different incubation periods The qualitative analysis was performed using normal PCR: PCRBIO 
Taq Mix red (PCRBiosystem, UK) kit as per as per the manufacturer recommendation. c DNA with a 
final concentration of 1μg from each sample (DNCB and PA treated) was used. The condition of the 
PCR reactions were 40 cycles and included: hold at 90 °C for 1 min, denaturation at 95 °C for 15 
sec, annealing at 62°C for 15 sec and elongation at 72°C for 30 sec.  
 
4.2.7. Quantitative polymerase chain reaction (qRT-PCR). 
1 μg of total cDNA was used to perform fluorescence-based Real Time PCR quantification, using 
2xqPCRBIO SyGreen Mix Lo-Rox (Pcrbiosystems,UK). The condition of the PCR reactions were 40 
cycles including: hold at 90 °C for  2 min, denaturation at 95 °C for 5 sec, annealing at 62°C for 28 
sec and elongation at 72°C for 30 sec. The data were normalised using the mRNA expression of the 
housekeeping gene named GAPDH. 
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 4.3. Results 
4.3.1. Cytotoxicity 
The highest concentration of the chemicals DNCB, PA, BZ and BC showing no 
cytotoxicity or 80% cell viability in the HaCaT cells was selected from the MTT assay 
(Figure 17), 10µM for each chemical. 
 
 
 
 
 
 
A 
B 
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Figure 17.  MTT assay: A. Benzalkonium Chloride (BC);B. Benzaldehyde (BZ); C. Phthalic anhydride (PA), 
control vs. 10uM, p= 0.0025 and control vs 100uM, p < 0.0001; D. 2,4-Dinitrochlorobenzene (DNCB), control 
vs. 10uM, p= 0.0025 and control vs 100uM, p < 0.0001.Error bars are mean +/-SD.  
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4.3.2. Primer design 
 
Two pairs of primers were designed by NCBI software 
(http://www.ncbi.nlm.nih.gov)based on the mRNA nucleotide sequences for each of GST-pi 
and GAPDH (housekeeping gene) gene as follows: 
 
Table 4. Designed Primers for GST-pi and GAPDH genes 
GST-pi (1) Primer1 
Reverse primer CAACCCTCACTGTTTCCCGT 
Forward primer GGAGACCTCACCCTGTACCA 
 
GAPDH (1) Primer1 
Reverse primer TGCAACCGGGAAGGAAATGA 
Forward primer TTCCCGTTCTCAGCCTTGAC 
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4.3.3. Qualitative determination of the designed GSTpi primers using control, 
DNCB and PA treated samples  
Agarose gel electrophoresis was used for qualitative analysis of the specificity of the 
designed GST-pi primers using the standard, control, DNCB and PA treated samples. The 
expected product corresponds to a size of 460 bp. The images of the agarose gels, visualised 
using a UV spectrophotometer, have shown the expected product in all the samples (treated 
with DNCB and PA and control), including the used standard (Figure 18). 
 
 
 
 
 
Figure 18. Qualitative analysis of primer specificity using agarose gel electrophoresis of A- HaCaT 
cells treated with DNCB; B- analysis of primer specificity using agarose gel electrophoresis of standard sample 
of untreated HaCaT and C- analysis of primer specificity using agarose gel electrophoresis of HaCaT cells 
treated with PA with different incubation periods; cells incubated for 24h   
 
 
4.3.4. Class pi (GST Pi) mRNA expression  
Although measuring protein expression and activity is a more accurate method to 
determine gene function, monitoring the mRNA level still can be easier, sensitive enough and 
convenient to be performed in the laboratory.  Keratinocytes, HaCaT cells (CLS cell line 
 
B A 
C 
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service, Germany) were subjected to DNCB and PA treatment (same dose) for different 
incubation periods. The expression level of mRNA was recorded using the Real Time PCR 
(qPCR) technique, generating a standard curve using untreated standard HaCaT cells 
incubated for 24 h at 37 °C, 5% CO2 ( Figure 19). 
The standard curve was obtained by performing qPCR on samples (HaCaT untreated 
cells for 24 h) with known DNA concentration (30ng/μl stock cDNA). A series of DNA 
standard dilutions were prepared in the following ratios: 1:5; 1:25; 1:125; 1:625; 1:3125 and 
no NT -template sample (no DNA sample).  The control and chemically treated samples were 
prepared at a 1:100 ratio and their expression calculated based on the plotted standard curve. 
A
B
Figure 19. Standard cDNA melting curve, A and standard curve, B performed on untreated HaCaT 
cells using the designed GSTpi primers.  
  
The analysed expression level of mRNA of treated (DNCB and PA) and untreated 
(control) cells are represented in figure 20 and figure 21 respectively.  
The mRNA level of the DNCB treated cell - dramatically increased during the first 30 
minutes of the treatment, reaching approx. 0.125 copies/μg. During the second 30 minutes the 
level of mRNA started to reduce sharply with more than 50% reaching 0.05 copies/μg. 
A 
B 
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Interestingly, the decrease in the level of mRNA continued up to 2h of incubation, followed 
by a gradual increase to 0.05 copies/μg during the 3th hour, moving to 0.09 copies/μg at the 4 
hours of incubation. During the 6th hour of incubation the level of mRNA was indicated to be 
approx 0.062 copies/μg, which is a decreased of 31% from the level recorded at 4 hour 
incubation. The mRNA level continued to decline and recorded 0.019 copies/μg at - 24 hours 
of incubation (Figure 20).  
 
Figure 20. mRNA expression level of Gluthatione-S-transferase (Pi), phase II metabolic enzyme (GST-pi) of 
keratinocytes (HaCaTa cell line ) using qRT-PCR treated with DNCB at different incubation time (Raw data 
Table 7 Appendix) . 
 
The mRNA level of HaCaT cells treated with phthalic anhydride (PA) did not show a 
sharp change in the mRNA level across the 24-hour incubation. The mRNA level was 
recorded at around 0.017 copies/μg with a higher mRNA level recorded at 24 hours 
incubation (0.027 copies/μg) (Figure 21). 
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Figure 21. mRNA expression level of Gluthatione-S-transferase (Pi), phase II metabolic enzyme (GST-
pi) of keratinocytes (HaCaT cell line ) using qRT-PCR treated with PA at different time incubation. Raw data 
Table 8 Appendix. 
 
Untreated HaCaT cells were used as a control for comparing the level of mRNA 
expression. 
 
4.4. Discussion  
4.4.1. In vitro examination of induced metabolic enzymes (XME phase II) 
Many studies have proved that keratinocytes and/or fibroblasts can be used as a 
promising tool to examine the immune responses, and molecular signalling together with 
metabolic conversion of sensitisers. GST phase II enzymes were proved to have the ability to 
reduce the electrophilic potential of chemicals (Lutz et al., 2001). Modification of signalling 
proteins involved in the molecular response to different sensitisers has been directly 
associated with the detoxification process. The Keap1-Nrf2-ARE signalling pathway was 
found to be the main cellular defence against cellular stress, enhancing the expression of 
phase II XME.  
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Research have shown that metabolic enzymes in keratinocytes are involved in preventing 
tissue damage from oxidative stress. In vivo assays have suggested that GST P and Mu 
metabolic enzymes can be highly expressed in response to contact allergens, in addition to 
their ability to be detected in HaCaT cells at the genomic and proteomic level (Hewitt et 
al.,2013). The Study by Jacquoilleot et al., 2015 looked at the expression of glutathione, a 
prominent antioxidant and cofactor for an important metabolic enzyme Glutathione-S-
Transferase, as a response to an exposure to extreme sensitisers such as 1-chloro-2,4-
dinitrobenzene (DNCB), 1-fluoro-2,4-dinitrobenzene (DNFB) and 1-bromo-2,4-
dinitrobenzene (DNBB). The investigation involved measuring the level of glutathione 
(GSH) in HaCaT cells and 3D Reconstructed Human Epidermis (RHE), as a result of which 
DNCB showed the higher potency. DNCB led to depletion of GSH within the first two hours, 
followed by a gradual increase with the highest level of GSH being recorded at 24h (Jacquoilleot 
et al. ,2015).  
In the current study, the expression of the GST P isoform was determined using the qRT-PCR 
molecular technique. The mRNA level was measured following incubation of keratinocytes 
(HaCaT cells) with two different potential chemicals: DNCB (2,4-Dinitrochlorobenzene) and 
PA (Phthalic anhydride). Both DNCB and PA are well known contact sensitisers. DNCB is 
known as an extreme sensitiser able to cause skin allergy, where as PA is strong sensitiser 
where the level of damage depends on the length of contact. The study was carried out using 
the well-established qRT- PCR technique to monitor the level of GST P mRNA expression as 
a result of exposure to extreme and strong skin sensitisers (Natsch et al., 2013). HaCaT cells 
were treated with 10 μM DNCB and PA where GST Pi mRNA level of expression was 
monitored at different time intervals.  
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The current study attempts to build a potential foundation for the use of in vitro techniques, in 
particular qRT-PCR, to monitor the extent of expression of the GST P gene in mRNA in 
response to treatment with DNCB and PA over different time periods. In addition to their  
different potencies DNCB and PA have different binding mechanisms: DNCB is known to 
bind to lysine and cysteine residues, whereas PA binds preferentially to lysine residues. The 
covalent modification of the Keap-1 protein by different electrophiles has been proved to 
increase the expression of various XME phase II enzymes, resulting in the induction of ARE-
dependent genes responsible for antioxidant regulation  including GST (Migdal et al., 2013; 
Natsch et al., 2013). 
 During the first 30 min of exposure with DNCB (an extreme sensitiser), GST P has shown a 
high expression in comparison with the control (uninduced sample). During the first hour of 
incubation the level of GST P sharply dropped down, reaching its lowest level after 2 hours 
of incubation, but it remained higher in comparison with the uninduced control sample. The 
level of GST P expression was higher after each different incubation time period across all 
the samples treated with DNCB. Clearly DNCB was able to modify the KEAP 1 protein and 
induce GST P gene expression as a response. The research study by Chia et al., 2010; 
Wakabayashi et al., 2004 investigated the fact that the modification of only certain residues is 
required in order to observe  Keap-1 modification and dissociation from Nrf2, where the 
latter translocates to the nucleus. During the third to the fourth hour of incubation the 
activation of a recovery mechanism was indicated and the expression of the GST P gene 
started to increase again. The large decrease after the sixth hour of incubation suggests the 
possibility of the activation of an additional mechanism after prolonged incubation with the 
extreme chemical DNCB. Chia et al., 2010 studied the NF-kb inflammatory pathway in 
response to drug treatments. The NF-kb pathway  has been proved to control the expression 
of inflammatory genes, cytokines and to contribute to cell survival. In the presence of a drug, 
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the NF-kb protein is inhibited, preventing it from binding to the kb regulatory element, 
interrupting the transcription of anti-apoptotic and antioxidant genes, causing cell death. 
These lead to cell protection by the Keap1-Nrf2 pathway. The decrease in the level of GST 
gene expression suggested that, if cell protection by the Keap1-Nrf2 pathway is 
overwhelmed, cell death may be induced due to the inhibition of NFkb (Figure 11- 
Supplement data). 
Phthalic anhydride is a strong sensitiser, known to bind specifically to lysine residues. PA 
treated cells showed more constant GST P transcription across the different incubation time 
periods, but a higher expression in comparison with the untreated samples.  
The Keap-1 protein consists of 624 amino acid residues, of which 4% are cysteine and 2.4% 
are lysine amino acids. In other words, the number of cysteine residues is almost double that 
of lysine (National Centre For Biotechnology Information).  Further experiment focusing on 
the 3D tertiary structure of the Keap-1 protein is suggested in order to identify possible lysine 
residues that could be targeted by PA. DNCB appeared to be a more potent Nrf2 activator in 
compare to with PA. Modification of the Keap-1 protein by DNCB has been investigated by 
Capple, 2012, but according to my knowledge the same investigation has not been applied to 
PA.  
The present investigation suggested the possibility of using RT-qPCR in order to distinguish 
between chemicals with different potencies and binding mechanisms. In order to make a final 
conclusion and confirm the above results, additional experiments need to be carried out, and 
the effect of DNCB and PA on Nrf2 and NFkb should be investigated further using 
keratinocytes (HaCaT cells). Secondly, studying the 3D tertiary structure of Keap-1 can be 
carried out, possibly leading to an understanding of how it is modified by PA. On the another 
hand  an assessment should be carried out of the effect on the expression of the GST P gene 
of additional chemicals with known potencies and binding mechanisms. 
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5.1. Characterisation of the human skin proteome 
 
The data obtained from protein profiling of human skin showed that proteins from both fractions 
(S9 and non-S9) are involved in various toxicological pathways such as inflammation, IL-
1/4/6 signalling, KEAP 1-NRF2, oxidative stress, EGFR1 signalling, MAPK signalling, 
prostaglandin synthesis and regulation.  In my investigation I have used the information 
obtained from the skin proteome to identify the proteins involved in toxicological pathways 
using the available up-to-date publications. These proteins can be used as model proteins for 
further investigation by tracking their expression on gene and protein level as a result of 
treatments with chemicals of different categories. In vitro techniques such as DNA 
microarray; qPCR; SDS-Page and Western Blotting can be used to identify and record any 
changes in the expression of selected genes and/or proteins between treated and untreated 
samples. As a future plan the same quantified and analysed skin samples can be treated with 
chemicals with different potency (time and dose dependent) and GelC-MS/MS analysis can 
be used to track any shift of the MS spectrum between treated and untreated samples. The 
analysis may provide valuable insights into the levels of nucleophilic residues of a key proteins; these 
residues are potential targets for electrophilic chemicals or metabolites, the product(s) of which 
lead(s) to skin sensitisation. I could not think of taking this approach as it requires continuous 
access  to MS apparatus and  its accompanying MS data analyser to study the obtained 
results. Unfortunately the University of Bedfordshire does not have these facilities available.     
On the another hand the research can be further extended and the experiment repeated 
by the identification, quantification and analysis of the skin proteome from a  larger number 
of skin donors. In this way a better picture can be obtained and further confirmation of the 
human skin proteome composition will become available. Protein Discoverer is a peptide 
characterisation software provided by Thermo Scientific, which is able to identify and study 
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protein molecules in depth using mass spectrometry data. Information can be obtained at the 
protein and peptide level, providing protein characterisation, relative quantification and fast 
analysis of complex protein mixtures including any post translational modification (PTM). 
Protein Discoverer can be used for the analysis of the identified proteins, providing 
meaningful information about gene ontology (GO) classification and literature references. In 
this way, a larger amount of data can be analysed at the same time using MS raw data (Mass 
Informatics Platform for Protein Scientists, 2017).    
  These findings may lead to deeper studies of these proteins and target them in vitro as 
specific “sensors-markers” at a specific toxicological endpoint. 
 
5.2. In chemico approach by Top-down mass spectrometry 
 
New results have shown more sites on APG able to bind DNCB under physiological 
condition (32 ᵒC). An additional experiment has been performed, where 25 chemicals (with 
various sensitising potencies and binding mechanisms (which bind preferentially either to 
cysteine or lysine or to both) were incubated with APG under physiological conditions, in 
order to identify the chemicals that would bind to APG, and possibly to identify their binding 
locations on the protein. In this way we can obtain a wider picture of the potential to use this 
analytical technique to predict the sensitising potency of chemicals. 
In order to develop reactivity assay it is very important to consider whether the studied 
chemical will be used as pure (on its own) or with a combination  with other chemicals that 
can be present in a trace or higher quantities. In order to screen a chemical in samples of 
multi-component products, the reactivity assay has to be developed with the excess of the 
sample. In this case if the chemical of interest is not very reactive a significant nucleophilic 
depletion will still be observed. However if the  chemical is used as a pure substance within a 
92 
 
sample, an excess of the nuclephile has to be used. In this case any minor impurity in the 
sample will not interfere with the final results (David and Basketter, 2009). 
Further experiments can be performed on APG incubated with those chemicals 
(showing positive results in the above experiment) over time or dose course under 
physiological conditions, to quantitatively elucidate haptenisation pathways under different 
starting conditions 
A different model protein, such as albumin or keratin, could be selected for additional 
study. 
These studies would provide more understanding of the mechanism of protein-hapten 
formation and any specific bindings between sensitisers and proteins, to achieve better 
quantification to predict skin sensitisation.  
The study of the binding mechanisms of biological molecules of known structure to 
chemicals of different potencies is one of the main stages of identifying a potential drug as  a 
therapeutic agent. Computational (biological) methods underline the ability of developing 
visual computer models that explain how the compounds bind to the target molecules 
(proteins). Molecular docking can be used to suggest the conformation of the compound and 
give information on its 3D orientation and all the possible binding sites. If the structure of the 
target molecule is known, then a series of virtual chemicals can be screened in order to 
identify those that can provide a good shape for binding (Ruiz Carmona et al., 2014). With 
knowledge of the 3D appearance of a target protein and its possible binding sites, virtual 
screening can be used to test a series of candidate compounds that are expected to bind to the 
target molecule. The data can be further validated by other experimental methods (Biesiada et 
al., 2011; Yin and Loo, 2010). Computational biology as a part of the in silico approaches for 
testing skin sensitisers will facilitate future determination of protein-hapten interaction. Since 
the structure of the protein-hapten complex is of great importance in toxicology, virtual 
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screening can help not only to identify the binding site, but also to study the mechanism of 
interaction between proteins and haptens, which can be used  to categorise different chemicals 
based on their potency  . 
 
5.3. In vitro examination of induced metabolic enzymes 
Research in this area has shown that metabolic enzymes in keratinocytes are involved 
in bio-activation, and conversely deactivation of contact allergens. In vivo assays have 
suggested that GST metabolic enzymes can play a major role in generating immune-reactive 
intermediates, in parallel with direct detoxification of immunogenic substances (Jacquoilleot 
et. al., 2015).  
Future research can focus on examining the induced expression of other metabolic 
enzymes (phase II and even phase I) at mRNA level by chemicals with different binding 
mechanisms and sensitising potency. The RT-qPCR technique, SDS-PAGE, Immunobloting 
assays and LC-MS/MS can be utilised to quantify mRNA and protein levels between control 
and chemical treated cells over a dose and/or time course. 
Chemicals and different substances compose the basis of various personal care and 
cosmetic products. The addition of these chemicals and  substances are usually to enhance the 
quality of the products and preserve them for longer period of time. Assessing the potential 
hazard of any chemical used by consumers is a crucial step before releasing these products to 
the market. It is important to remember that the sustainability of different individuals towards 
the chemicals used in cosmetic and personal care products is different usually affected by 
different factors. These factors are based on how the products are used, consumers' age, skin 
condition and even genetic factors.  
With the implementation of the 7th amendment of the EU Cosmetic Directive in 
2013, different approaches have been studied in order to reduce, refine, replace (3R's) the 
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current in vivo  approaches for assessing chemical potencies. The obtained results from this 
and other experiments proved that the allergic contact dermatitis  is a complex skin disorder 
that involves many different cells, toxicological pathways, genes and proteins. In order to 
understand all the skin biology and the mechanism of allergy in response to chemicals, an 
integrated in vitro, in chemico and in silico techniques have to be brought together for a 
possible more accurate characterisation of chemical potency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
6. REFERENCES 
About the OECD - OECD (2017). Oecd.org.(accessed on 7th July 2017) 
http://www.oecd.org/about/ 
 
Aeby, P., Ashikaga, T., Diembeck, W., Eschrich. D. and Gerberick, F. (2007), 
The COLIPA strategy for the development of in vitro alternatives: Skin sensitisation. Proc. 
6th World Congress on Alternatives & Animal Use in the Life Sciences, 375-379.  
 
Aleksic, M., Pease, K. C., Basketter, A. D. and Panico, M. (2007), Investigating protein 
haptenation mechanisms of skin sensitisers using human serum albumin as a model protein, 
Toxicology in Vitro 21, 723-733.  
 
Aleksic, M., Pease, C., Basketter, D. A., Panico, M., Morris, H. R. and Dell, A. (2008), 
Mass spectrometric identification of covalent adducts of the skin allergen 2,4-dinitro-1-
chlorobenzene and model skin proteins, Toxicology in Vitro 22, 1169-1176.  
 
Anderson, S. E., Siegel, P. D. and B.J. Meade, B. (2011). The LLNA: A brief review of 
recent advances and limitations. J Allergy (Cairo) doi: 10.1155/2011/424203,. 
 
Assuring Safety without Animal Testing: Skin Allergy Case Study - Overview Assuring 
Safety without Animal Testing: Skin Allergy Case Study - Overview. 
Asturiol, D. and Worth, A. (2011): The use of chemical reactivity assays in toxicity 
prediction. JCR scientific and technical report, doi 10.2788/32962 
Ban on Animal Testing - Growth - European Commission (2017). Growth. accessed on 24th 
September 2017 
Basova, L. V., Tiktopulo, E. I., Kashparov, I. A. and Bychkova, V. E. (2004). The 
Conformational State of Apomyoglobin in the Presence of Phospholipid Vesicles at Neutral 
pH. Molecular Biology, 38, 272–280. 
Basketter, D. A., Evans, P., R.J.Fielder, R. J., Gerberick, G. F., DearmanaI, R. J. and 
Kimbere, I. (2002). Local lymph node assay — validation, conduct and use in 
practice. Food Chem Toxicol, 40, 593-598. 
Basketter, A. D. (2012), Non-animal approaches in skin toxicology, Arch Toxicol 86, 1159-
1160.  
Bensouilah, J. and Buck, P. (2006), Skin Structure and Function, pp. 4-11. UK: Radcliffe 
Publishing 
Biesiada J, Porollo A, Velayutham P, Kouril M, Meller J. (2011) Survey of public domain 
software for docking simulations and virtual screening. Human genomics, 5 (5), 497-505 
 
96 
 
Blacker, K. L., Olson, E., Vessey, D. A. and Boyer, T. D. (1991). Characterization of 
Glutathione S-Transferase in Cultured Human Keratinocytes. Journal of Investigative 
Dermatology, 97, 442–446. 
 
Bonifas, J., Hennen,J., Dierolf,D., Kalmes, M., Blomeke, B. (2010), Evaluation of 
cytochrom P450 (CYP1) and N-acetyltransferase 1(NAT1) activities in HaCaT cells : 
implications of development of in vitro techniques for predictive testing of contact 
sensitisers, Toxicology in vitro 24, 973-980 
Brohem, C. A., Cardeal, L. B. D. S., Tiago, M., Soengas, M. S., Barros, S. B. D. M. and 
Maria-Engler, S. S. (2010). Artificial skin in perspective: concepts and 
applications. Pigment Cell & Melanoma Research, 24, 35–50. 
Busheri, K., Marcoux Y., Tredget E., Li L., Zheng J., Ghoreishi M., Weinfeld M., 
Ghahary A.,(2002), Expression of a releasable form of annexin II by human 
keratinocytes.J.Cell Biochem, 86(4):737-47 
Casati, S., Worth, A., Amcoff, P., Whelan, M., (2013), EURL ECVAM Strategy for 
Replacement of Animal Testing for Skin Sensitisation Hazard Identification and 
Classification, Joint Research Centre of the European Commission 
Chapin, R. E., Boekelheide, K., Cortvrindt, R., Duursen, M. B. V., Gant, T., Jegou, B., 
Marczylo, E., Pelt, A. M. V., Post, J. N., Roelofs, M. J., (2013). Assuring safety without 
animal testing: The case for the human testis in vitro. Reproductive Toxicology, 39, 63–68. 
Chia, A. J., Goldring, C. E., Kitteringham, N. R., Wong, S. Q., Morgan, P. and Park, B. 
K. (2010). Differential effect of covalent protein modification and glutathione depletion on 
the transcriptional response of Nrf2 and NF-κB.Biochemical Pharmacology. 80, 410–421. 
Chipinda, I., Hettick, J. M. and Siegel, D. P. (2011), Haptenisation: Chemical reactivity 
and protein binding Journal of Allergy, doi:10.1155/2011/839682.  
 
Collet JF, Messens J.(2010), Structure, function, and mechanism of thioredoxin proteins, 
Antioxid Redox Signal. 13(8):1205-16 
 
Compton, D. P. and Kelleher, L. N. (2012), Spinning up mass spectrometry for whole 
protein complexes, Nature method, 9(11), 1065-1066.  
Copple, I. M. (2012). The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic 
Target? Adv. Pharmacol, 63, 43–79. 
Corsini, E., Roggen, LL.E., Galbiati, V., Gibbs, S. (2016) Alternative Approach for 
Potency Assessment: In Vitro Methods. Cosmetics 3(7), doi:10.3390 
97 
 
Cronin, M. T., Bajot, F., Enoch, S. J., Madden, J. C., Roberts, D. W. and Schwöbel, J. 
(2009). The in Chemico–In silicoInterface: Challenges for integrating experimental and 
computational chemistry to identify toxicity ATLA, 37, 513-521.  
 
Denecker, G., Ovaere, P., Vandenabeele, P. Declercq, W., (2009) Caspase-14 reveals its 
secrets. Department of molecular biology research, 180(3), 451-458 
 
Dietz L, Esser PR, Schmucker SS, Goette I, Richter A, Schnolzer M, Martin SF and 
Thierse HJ (2010), Tracking human contact allergens: from mass spectrometric 
identification of peptide-bound reactive small chemicals to chemical-specific native human T 
cell priming. Toxicological Sciences 117 (2):336-347. 
 
Esser, C., Gotz, C., (2013), Filling the gaps: need for research on cell specific xenobiotic 
metabolism in the skin, Arc.Toxicol, 10.1007/s00204-013-1031-7 
 
Eilstein J, Léreaux G, Budimir N, Hussler G, Wilkinson S, Duché D (2014). Comparison 
of xenobiotic metabolizing enzyme activities in ex vivo human skin and reconstructed human 
skin models from SkinEthic, Arch toxicol, 88(9), 1681-1694. 
Foucquier, J. and Guedj, M. (2015). Analysis of drug combinations: current 
methodological landscape. Pharmacology Research & Perspectives.3(3)  doi: 
10.1002/prp2.149 
From data set to meaningful biology (2017). TMT UK: Protein Center, Thermo scientific 
Janeway, C. A. (2003). Immunobiologie: le système immunitaire fondamental et 
pathologique. 5th ed. Paris: De Boeck. 
Jacquoilleot, S., Sheffield, D., Olayanju, A., Sison-Young, R., Kitteringham, N. R., 
Naisbitt, D. J. and Aleksic, M. (2015). Glutathione metabolism in the HaCaT cell line as a 
model for the detoxification of the model sensitisers 2,4-dinitrohalobenzenes in human 
skin. Toxicology Letters, 237, 11–20. 
Jong, W. H. D., Arts, J. H., Klerk, A. D., Schijf, M. A., Ezendam, J., Kuper, C. F. and 
Loveren, H. V. (2009). Contact and respiratory sensitizers can be identified by cytokine 
profiles following inhalation exposure. Toxicology, 261, 103–111. 
Haniffa, M., Gunawan, M., Jardine, L. (2015). Human skin dendritic cells in health and 
disease. Journal of Dermatological Science, 77, 85-92 
 
Hewitt N., Edward, R., Fritche,E., Gobel, C., Aeby B., Scheel, J., Reisinger, K., 
Ouidraogo, G., Duche, D., Eilstein, J., Latel, A., Kinny, J., Moore, C., Kuehln, J., 
Barroso, J., Fautz, R., Pfuhler, S.,(2013), Use of human in vitro skin models for accurate 
and ethical risk assessment: metabolic consideration,  Toxicological science, 133(2), 209-217 
Ioannides, C. (2002). Xenobiotic Metabolism: An Overview. Enzyme Systems that 
Metabolise Drugs and Other Xenobiotics 1–32. 
98 
 
Gerberick, F. G., Vassallo, D. J., Foertsch, L. M., Price, B. B. and Chaney, G. J. (2007), 
Quantification of chemical peptide reactivity for screening contact allergens: A classification 
tree model approach, Toxicological Science, 97(2), 417-427. 
 
Gerberick, G. F., Troutman, J. A., Foertsch, L. M., Vassallo, J. D., Quijano, M., 
Dobson, R. L. M., Goebel, C. and Lepoittevin, J.-P. (2009). Investigation of Peptide 
Reactivity of Pro-hapten Skin Sensitizers Using a Peroxidase-Peroxide Oxidation 
System. Toxicological Sciences, 112, 164–174. 
 
Goebel, C., Aeby, P., Ade, N., Alépée,N., Aptula, A.,  Araki, D., Dufour, E.,  Gilmour, N.  
Hibatalla, J., Keller, D., Kern, P., Kirst, A., Marrec-Fairley, M., Maxwell, G., Rowland, 
J., Safford, B., Schellauf, F., Schepky, A., Seamanm, C., Teichert, T.  
 
 
Gotz, C., Pfeiffer, R., Tigges, J., Blatz, V., Jackh, C., Freytag, E., Fabien, E., Landsiedel, 
R., Merk, H., Krutmann, J., Edwards, R., Pease, C., Joebel, C., Hewitt, N., Fritsche, E. 
(2012a), Xenobiotic metabolism capacity of human skin in cmparison with a 3D epidermis 
model and keratinocytes- based cell culture as in vitro alternative for chemical testing: 
activating enzymes (PhaseI). Experimental Dermatology, 21, 358-363 
 
 
Gotz, C., Pfeiffer, R., Tigges, J., Ruwiedel, K., Hubbenthal, U., Merk, H., Krutmann, J., 
Edwards, R., Abel., G., Pease, C., Joebel, C., Hewitt, N., Fritsche, E. (2012b). Xenobiotic 
metabolism capacity of human skin in cmparison with a 3D epidermis model and 
keratinocytes- based cell culture as in vitro alternative for chemical testing: phase II enzymes. 
Experimental Dermatology, 21, 364-369 
 
 
Hewitt, N. J., Edwards, R. J., Fritsche, E., Goebel, C., et al., (2013), Use of human in vitro 
skin models for accurate and ethical risk assessment: metabolic considerations. Toxicological 
Science, 133(2): 209-217. 
 
Hullete, B. C., Gerberick, G. F. and Ryan, C. A. (2002), Elucidating changes in surface 
markers expression of dendritic cells following chemical allergen treatment.Toxicol. Appl. 
Pharmacol, 182, 226-233.  
 
Jayaprakash P, Dong H, Zou M, Bhatia A, O'Brien K, Chen M, Woodley DT, Li W. 
(2015) Hsp90α and Hsp90β Co-Operate a Stress-Response Mechanism to Cope With 
Hypoxia and Nutrient Paucity during Wound Healing, J Cell Sci. 
 
Jeonge, Y., An, S., Shin, K. and Lee, T. (2013). Peptide reactivity assay using 
spectrophotometric method for high-throughput screening of skin sensitisation potential of 
chemical hapten. Toxicology in Vitro 27, 264-271.  
 
Kelleher NL (2004), Top-down proteomics. Analytical Chemistry: 197A-203A. 
 
 
 
99 
 
Kellie, J. K., Tran, J. C., Lee, J., Ahlf, D. R., Thomas, H. M., Ntai, I., Catherman, A. C., 
Durbin, K. R., Zamdborg, L., Vellaichamy, A. et al. (2010). The emerging process of top 
down mass spectrometry for protein analysis: Biomarkers, protein-therapeutics, and 
achieving high throughput Mol. Biosyst 6(9), 1532-1539.  
 
Kimura, J., Hayakari, M., Kumano, T., Nakano, H., Satoh, K. and Tsuchida, 
S. (1998). Altered glutathione transferase levels in rat skin inflamed due to contact 
hypersensitivity: Induction of the alpha-class subunit 1.. Biochem J. 335(3), 605-610. 
 
 
Lodygin, D., Yazdi, A., Sander, C., Herzinger, T., Hermeking, H., (2003). Analysis of 14-
3-3  expression in hyperproliferative skin diseases reveals selective loss associated with 
CpG-methylation in basal cell carcinoma. Oncogene, 22,5519-5524 
 
Lutz, W., Tarkowski, M., Nowakowska, E. (2001). Genetic polymorphism of glutathione s-
transferase as a factor predisposing to allergic dermatitis. Med.Pro, 52, 45–51 
Luu-The, V., Duche, D., Ferraris, C., Meunier, J. R., Leclaire, J. and Labrie, 
F. (2009). Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the 
reconstructed skin models episkin and full thickness model from episkin.. J Steroid Biochem 
Mol Biol 116(3-5), 178-186. 
Maheshwari, S. (2013). The cosmetic market current and future outlook. Business 
consultancy service, RNCOS 
Mass Informatics Platform for Protein Scientists (2017). TMT UK: Protein Discoverer, 
Thermo scientific. 
Maxwell, G. and MacKay, C. (2011). Skin sensitisation. Modelling the human adverse 
response. Bedford, MK: Unilever. 
Migdal, C., Botton, J., Ali, Z. E., Azoury, M.-E., Guldemann, J., Gimenez-Arnau, E., 
Lepoittevin, J.-P., Kerdine-Romer, S. and Pallardy, M. (2013). Reactivity of Chemical 
Sensitizers Toward Amino Acids In Cellulo Plays a Role in the Activation of the Nrf2-ARE 
Pathway in Human Monocyte Dendritic Cells and the THP-1 Cell Line. Toxicological 
Sciences, 133, 259–274. 
Millington P.F. and Wilkinson R. (2009) Skin. New York: Cambridge University press 
Misra, R. V. and Gaulton, T. (2015). Tandem Mass Spectrometry Analysis as an Approach 
to Delineate Genetically Related Taxa, with Specific Implication for Differentiating 
Escherichia coli from amongst the Complex Enterobacteriaceae Family. Journal of 
Proteomics & Enzymology, 4. 
Montagna, W. (1974). The Structure and Function of Skin. 3rd ed. New York: Academic 
press. 
100 
 
National Center For Biotechnology Information. Ncbi.nlm.nih.gov. N.p., 2016. Web.  01 
Oct. 2016. 
Natsch A (2010), The Nrf2-Keap1-ARE toxicity pathway as a cellular sensor for skin 
sensitizers—functional relevance and a hypothesis on innate reactions to skin sensitizers, 
Toxicological Sciences, 113 (2): 284-292. 
 
Natsch, A., Ryan, C. A., Foertsch, L., Emter, R., Jaworska, J., Gerberick, F. and Kern, 
P. (2013). A dataset on 145 chemicals tested in alternative assays for skin sensitization 
undergoing prevalidation. Journal of Applied Toxicology, 33, 1337-1352 
Parkinson, E., Skipp, P., Aleksic, M., Garrow, A., Dadd, T., Hughes, M., Clough, G. and 
O′connor, C. D. (2014). Proteomic Analysis of the Human Skin Proteome after In Vivo 
Treatment with Sodium Dodecyl Sulphate. PLoS ONE 9. 
Pease, C., Thain, E. and Zazzeroni, R. (2010), Reactivity assays – dealing with substances 
and samples in anworld – the solution and the real problem in vitro. Contact Dermatitis, 62, 
256-257 
 
Piersma, S.R., Warmoes, M.O., de Wit, M., de Reus,I.,  Knol, J.C., Jiménez, C.R. (2013). 
Whole gel processing procedure for GeLC-MS/MS based proteomics. Proteome 
Science,11:17 
 
Pigors M, Schwieger-Briel A, Cosgarea R, Diaconeasa A, Bruckner-Tuderman L, Fleck 
T, Has C.(2014),Desmoplakin mutations with PalmoplantarKeratoderma, Woolly Hair and 
Cardiomyopathy,Acta.Derm.Venereol, 95(2), 337-340 
 
Ramadoss, P., Marcus, G., Perdew, G., (2005), Role of the aryl hydrocarbon receptor in 
drug metabolism. Expert Opin.DrugMetab.Toxicol., 1(1), 1-13 
 
REACH - Growth - European Commission (2017). Growth, (accessed on 15th September 
2017), https://ec.europa.eu/growth/sectors/chemicals/reach_bg 
 
Roberts, D. W. and Basketter, D. A. (2009), Reactivity assays, substances, samples and  
alternatives: Why should we care? Contact Dermatitis, 61, 310-311.  
 
Rose, J. R., Damoc, E., Denisov, E., Makarov, A., Albert, J. R. and Heck, A. J. R. 
(2012), High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies, Nature 
method, 9(11), 1084-1088.  
Ryan, A.C., Kimber, I., Basketter, D.A., Pallardy, M., Gildea, L.A., Frank Gerberick, 
G., (2007). Dendritic cells and skin sensitization: Biological roles and uses in hazard 
identification, Toxicology and applied pharmacology, 221, 384-394 
 
Ru, Q. C., Zhu. L.A., Siberman, J., Shriver, C.D. (2006). Label-free Semiquantitative 
Peptide Feature Profiling of Human Breast Cancer and Breast Disease Sera via Two-
dimensional Liquid Chromatography-Mass Spectrometry. Molecular & Cellular 
Proteomics, 5, 1095–1104. 
101 
 
 
Saint-Mezard,P., Rosieres, A., Krasteva,M Berard,V Budois,B., Kaiserlian, D., Nicolas, 
J., (2004) ), Allergic contact dermatitis, Eur J Dermatol, 14, 284-95 
(SCHER) Scientific Committee on Health and Environmental Risks (2011). Toxicity and 
Assessment of Chemical Mixtures. European commission. 
Schnuch A, Geier J, Lessmann H, Uter W, Arnold R, Mackiewiecz, M (2004): 
Untersuchungen zur Verbreitung umweltbedingter Kontaktallergien mit Schwerpunkt im 
privaten Bereich, Forschungsbericht 29961219, Umweltbundesamt, Berlin 
 
Schouest, J. M., Luu, T. K. and Moy, R. L. (2010). Improved texture and appearance of 
human facial skin after daily topical application of barley produced, synthetic, human-like 
epidermal growth factor (EGF) serum. J Drugs Dermatol. 11(5), 613-620. 
Sergio Ruiz-Carmona, Daniel Alvarez-Garcia, Nicolas Foloppe, A. Beatriz Garmendia-
Doval, Szilveszter Juhos, Peter Schmidtke, Xavier Barril , Roderick E. Hubbard ,S. 
David Morley (2014)  rDock: A Fast, Versatile and Open Source Program for Docking 
Ligands to Proteins and Nucleic Acids. PLOS Computational Biology 
Siemionow, M. and Einsenmann-Klein, M. (2016). PLASTIC AND RECONSTRUCTIVE 
SURGERY. Springer London LTD. 
Stacey E. Anderson, ES., Siegel, D.P., Meade, J.B., (2011), The LLNA: A Brief Review of 
Recent Advances and Limitations. Journal of Allergy, doi:10.1155/2011/424203 
 
Taverna, D., Nanney, B., Pollins, A. C., Sindona, G. and CapriolI, R. (2011), 
Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of 
human skin proteomic signaturesPubMed, 20(8), 642-647 
Tessier, N., Teissier, S. Weltzien, H.U., Winkler, P., Scheel, J. (2012). Guiding principles 
for the implementation of non-animal safety assessment approaches for cosmetics: Skin 
sensitisation, Regulatory toxicology and pharmacology, 63, 40-52 
The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to 
Proteins (2014). OECD Series on Testing and Assessment. doi: 10.1787/9789264221444-en 
 
 
Thyssen, J. P., Giménez-Arnau, E., Lepoittevin, J.-P., Menné, T., Boman, A. and 
Schnuch, A. (2012). The critical review of methodologies and approaches to assess the 
inherent skin sensitization potential (skin allergies) of chemicals Part III. Contact Dermatitis, 
66, 53–70. 
 
 
Tigges, J., Weighardt, H., Wolff, S., Gotz,C.,Forsets,I., Kohne,Z., Huebenthal, U., 
Merk,H., Abel,J., Haarmann-Stemmann,T., Krutmann,J., Fritsche,E., (2013). Aryl 
Hydrocarbon receptor repressor (AhRR) function revisited: repression of CYP1 activity in 
human skin fibroblasts is not related to AhRR expression. The society of investigative 
dermatology, 87-95 
 
102 
 
Troutman, A. J., Foertsch, M. L., Kern, S. P., Jian Dai, H., Q uijano, M., Dobson, R. L. 
M., Lalko, J. F., Lepoittevin, J. and Gerberick, G. F. (2011). The incorporation of lysine 
into the peroxidase peptide reactivity assay for skin sensitization assessments Toxicological 
Science, 122(2), 422-436 
 
Tortora GJ. and Grabowski SR. (1993) Principles of Anatomy and Physiology. 
HarperCollins College Publishers. 
 
Tončić, R.J., Lipozenčić, J., Martinac,I., Gregurić, S.(2011). Immunology of Allergic 
Contact Dermatitis, Acta Dermatovenerol Croat, 19(1), 51-68 
 
Vandebriel1, R.J. and van Loveren, H. (2010), Non-animal sensitization testing: State-of-
the-art. Critical Review in Toxicology, 40(5), 389-404. 
 
Van der Veen, J. P.T., van Loveren, H. and Ezendam, J. (2012), Applicability of 
keratinocytes gene signature to predict skin sensitising potential, Toxicology in Vitro, 27(1), 
314-322 
 
van Eijl, S., Zhu Z., Cupitt, J., Gierula,M., Go¨ tz, C.,Fritsche,E., Edwards,  E (2012), 
Elucidation of Xenobiotic Metabolism Pathways in Human Skin and Human Skin Models by 
Proteomic Profiling. PloS One, 7(7),1-13 
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, 
A., Yamamoto, M., Kensler, T. W. and Talalay, P. (2004). Protection against electrophile 
and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor 
modified by inducers. Proceedings of the National Academy of Sciences, 101, 2040–2045. 
Yin S , Loo JA. (2010) Elucidating the site of protein-ATP binding by top-down mass 
spectrometry. J Am Soc Mass Spectrum, 21(6), 899-907 
Zaidi, Z. and Lanigan, S. W. (2010). Dermatology in clinical practice. Dordrecht: Springer. 
 
Zhu, Z, Boobis, A.R. and Edwards, R. J. (2008a), Identification of estrogen-responsive 
proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics, 
Proteomics, 8:1987-2005 
 
Zhu Z, Edwards, R. J. and Boobis, A. R. (2008b), Proteomic analysis of human breast cell 
lines using SELDI-TOF-MS shows that mixtures of estrogenic compounds exhibit simple 
similar action (concentration additivity). Toxicology Letters,181:93-103 
 
Zuang, V., Schäffer, M., Tuomainen, A.M., Amcoff, P., Bernasconi, C., Bremer, S.,   
Casati, S., Castello, P., Coecke, P., Corvi, R., Griesinger, C., Roi, A.J., Kirmizidis, G., 
Prieto, P., Worth, A., Munn, S., Berggren, E., Whelan, M. (2010-2013), EURL ECVAM 
progress report on the development, validation and regulatory acceptance of alternative 
methods. Joint Research Centre of the European –Commission 
 
 
 
 
103 
 
7. List of Abbreviations  
ACD Allergic Contact Dermatitis  
ACN Acetonitrile  
AOP Adverse outcome pathways 
APG Apomyglobin 
BC Benzalkonium chloride 
BCA assay  
BZ Benzaldehyde 
CB Chlorobenzene 
CD4+ Cluster of differentiation 4 
CD83 Cluster of differentiation 83 
CD86 Cluster of differentiation 86 
CID Collision-induced dissociation 
CM Coumarin 
CMIR Cell mediated immune reaction  
COLIPA European Cosmetic, Toiletry and Perfumery Association 
DC Dendritic cells 
DC Dihydrocoumarin 
DM 2-Mercaptobenzothiazole 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNBC 2,4-dichloronitrobenzene 
DNCB 2-4-Dinitrochlorobenzen 
DP Dibenzoyl peroxide 
DPRA Direct peptide reactivity assay 
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EA Ethyl acrylate 
EDTA Ethylenediaminetetraacetic acid 
EG Eugenol 
EURL ECVEM European Union Reference Laboratory for alternatives to animal testing 
FA Formaldehyde 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase (Housekeeping gene) 
GST- Glutathione -S-transferase 
GST P Glutathione -S-transferase pi isoform 
GST M Glutathione -S-transferase mu isoform 
GST O Glutathione -S-transferase omega isoform 
GST A Glutathione -S-transferase alfa isoform 
h-CALT Human Cell Line Activation test 
HPA Health protecting agency 
HPLC High performance liquid chromatography 
HPLC/MS High performance liquid chromatography, mass spectrometry  
HSA Human serum albumin 
IE Isoeugenol 
IgG, IgM, IgE Immunoglobulin G,M,E 
IL-12 Interleukin 12 
IL 2 Interleukin 2 
IL1 Interleukin 1  
IL6 Interleukin 6 
IFNγ Interferon gamma   
K14 Cytokeratine 14  
KC keratinocytes  
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LTQ Linear ion trap mass spectrometer 
MA Maleic acid 
MASCOT Protein identification software of mass spectrometry data 
MB 2-Mercaptobenzothiazole 
MHC major histocompatibility complex 
MM Methyl methacrylate 
MS Methyl salicylate 
MTT assay [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] 
MW Molecular weight 
NCBI National Center for Biotechnology Information 
Non-S9 Non soluble protein fraction   
OECD Organisation for Economic Co-operation and Development 
PA Phthalic anhydride 
PBS Phosphate buffer saline 
PD p-Phenylenediamine 
PS Phenyl Salicylate 
qPCR Quantitative polymerase chain reaction 
QSAR quantitative Structure activity relationship  
REACH Registration, Evaluation and Authorisation of Chemicals 
SAR Structure activity relationship 
S9 Soluble protein fraction  
SDS Sodium dedocyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
TNF Tumour Necrosis factor 
U937/CD86 assay Myeloid U937 skin sensitisation test  
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Uniprot Universal protein knowledgebase  
XME Xenobiotic metabolic enzymes 
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Figure 22. The certificates of analysis of the 8 human skin samples provided by Biopredict International, France used in 
the skin proteome analysis 
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Table 5. Identification and quantitative expression overview of all proteins identified in S9 & NS9 fractions, based on the 
presence of  ≥2 different tryptic peptides identified in all the 8 donors. 
Proteins in S9 fraction Peptide Mol Weight NCBI identification 
Keratin, type II cytoskeletal 2 epidermal  18 65,433.90 NP_000414.2 
Histone H4  6 11,269.60 NP_778224.1 
Ig gamma-1 chain C region  6 36,105.00 PT0368 
Glyceraldehyde-3-phosphate 
dehydrogenase  3 36,053.40 CAA25833.1 
Ig kappa chain C region  3 11,608.60 P01834.1 
Histone H2B type 1-N  4 13,950.80 NP_003511.1 
Keratin, type II cytoskeletal 1  17 66,040.30 NP_006112.3 
Hemoglobin subunit beta  2 15,998.00 NP_000509.1 
Serum albumin  24 69,366.90 NP_000468.1 
Ig alpha-1 chain C region  2 37,754.70 B45874 
Keratin, type I cytoskeletal 10  14 58,828.80 NP_000412.3 
Actin, cytoplasmic type 5  6 41,851.00   
Myosin-9  2 226,537.50 NP_002464.1 
Ubiquitin-40S ribosomal protein S27a  3 17,965.60 NP_001129064.1 
Gelsolin  4 85,697.80 NP_000168.1 
Phosphatidylethanolamine-binding protein 
1  2 21,056.90 NP_002558.1 
Keratin, type I cytoskeletal 14  8 51,562.50 NP_000517.2 
Peptidyl-prolyl cis-trans isomerase A  5 18,012.90 NP_066953.1 
Transaldolase  2 37,541.70 NP_006746.1 
14-3-3 protein sigma  7 27,774.80 
NP_006133.1 
   
Bleomycin hydrolase  3 52,562.60 NP_000377.1 
60S acidic ribosomal protein P0  3 34,371.40 NP_444505.1 
Keratin, type I cytoskeletal 9  2 62,065.90 NP_000217.2 
Serpin B12  3 46,277.70 NP_536722.1 
40S ribosomal protein S3  3 29,945.30 NP_001243731.1 
L-lactate dehydrogenase A chain  3 36,689.20 NP_005557.1 
Proteasome subunit beta type-1  2 26,490.50 NP_002784.1 
Prelamin-A/C  4 74,140.70 NP_733821.1 
Zinc-alpha-2-glycoprotein  5 34,258.60 NP_001176.1 
60S ribosomal protein L5  4 34,363.50 NP_000960.2 
40S ribosomal protein SA  3 33,021.30 NP_001012321.1 
Annexin A2  12 38,606.10 AAH68065.1 
Fructose-bisphosphate aldolase C  2 39,420.60 
NP_005156.1 
   
40S ribosomal protein S18  3 17,719.30 NP_072045.1 
60S ribosomal protein L12  4   NP_000967.1 
Alpha-1-antichymotrypsin  3 47,653.00 NP_001076.2 
Pyruvate kinase PKM  7 57,937.50 NP_001193728.1 
Junction plakoglobin  10 81,801.90 NP_068831.1 
Epiplakin  13 555,615.40 NP_112598.3 
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Peptidyl-prolyl cis-trans isomerase B  4 18,012.90 
NP_000933.1 
   
Malate dehydrogenase, cytoplasmic  2 36,426.90 NP_001186040.1 
Alpha-2-macroglobulin  2 163,289.90 NP_000005.2 
Protein disulfide-isomerase A3  4 56,784.60 NP_005304.3 
Complement C3  3 187,149.10 NP_000055.2 
Collagen alpha-1(XVIII) chain  3 178,187.70 NP_001846.3 
Protein disulfide-isomerase  5 57,118.10 NP_000909.2 
60S ribosomal protein L10a  3 24,832.00 NP_009035.3 
Fructose-bisphosphate aldolase A  3 39,420.60 CAA30270.1 
Hemopexin  2 51,676.50 NP_000604.1 
14-3-3 protein zeta/delta  5 27,745.90 
  
NP_001129174.1 
  
Actin-related protein 3  3 47,371.90 NP_065178.1 
Gamma-glutamylcyclotransferase  4 21,008.00 NP_076956.1 
Heat shock 70 kDa protein 1B  12 70,230.20 NP_005337.2 
14-3-3 protein epsilon  4 29,175.00 NP_006752.1 
Transitional endoplasmic reticulum 
ATPase  7   NP_009057.1 
Elongation factor 2  5 50,119.40 NP_001952.1 
Peroxiredoxin-1  7 22,110.90 NP_859048.1 
Glutathione S-transferase Mu 3  5 25,746.50 NP_000840.2 
Alpha-2-macroglobulin-like protein 1  3 161,108.20 
  
NP_653271.2 
   
Triosephosphate isomerase  5 30,790.80 NP_000356.1 
Periostin  4 93,318.00 NP_006466.2 
Alpha-enolase  8 47,170.20 NP_001419.1 
Plectin  13 531,783.90 NP_112598.3 
Serotransferrin  22 77,064.30 NP_001054.1 
Tripartite motif-containing protein 29  5 65,835.70 NP_036233.2 
Glucose-6-phosphate isomerase  3 31,085.70 NP_001171651.1 
Desmocollin-1  6 99,988.10 NP_077739.1 
WD repeat-containing protein 1  2 66,193.20 NP_059830.1 
Caspase-14  6 27,679.80 NP_036246.1 
Thioredoxin  2 11,737.30 
  
AAF87085.1 
   
Myosin light polypeptide 6  2 16,929.80 NP_066299.2 
Proteasome subunit alpha type-7  4 29,586.00 
NP_002783.1 
   
Annexin A7  2 52,740.50 AAH02632.1 
Complement C3  7 187,149.10 
NP_000055.2 
   
Cathepsin D  4 44,553.00 NP_001900.1 
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Serpin B5  8 42,101.80 NP_002630.2 
Calpain-1 catalytic subunit  5 81,892.60 NP_001185798.1 
Protein-glutamine gamma-
glutamyltransferase E 7 89,786.00 NP_003236.3 
Alpha-actinin-4  14 41,851.00 NP_004915.2 
Heat shock protein HSP 90-beta  3 84,778.20 NP_031381.2 
Ribonuclease inhibitor  5 49,974.40 NP_976320.1 
Dihydrolipoyl dehydrogenase, 
mitochondrial  2 61,399.70   
Fibrinogen beta chain  5 55,928.60 NP_005132.2 
Annexin A1  7 38,715.90 NP_000691.1 
Collagen alpha-3(VI) chain  20 343,667.40 NP_476508.2 
Transforming growth factor-beta-induced 
protein ig-h3  3 74,682.90 NP_000349.1 
Fibronectin  4 262,616.90   
Ig mu chain C region  3 49,305.70 S37768 
Fatty aldehyde dehydrogenase  4 54,849.80 NP_001026976.1 
Phosphoglycerate kinase 1  5 44,615.30 NP_000282.1 
Glutamate dehydrogenase 1, mitochondrial  10 61,399.70 NP_005262.1 
Annexin A5  4 35,938.60 NP_001145.1 
Annexin A4  6 35,884.30 NP_001144.1 
Heterogeneous nuclear ribonucleoprotein 
U-like protein 1  2 96,003.10 NP_008971.2 
X-ray repair cross-complementing protein 
6  5 69,846.40 NP_001460.1 
Catalase  10 59,756.50 NP_001743.1 
Rab GDP dissociation inhibitor beta  7 50,584.10 NP_001108628.1 
Ubiquitin-like modifier-activating enzyme 
1  4 117,850.30 NP_003325.2 
Ras GTPase-activating-like protein 
IQGAP1  4 189,258.60 NP_003861.1 
Ceruloplasmin  3 122,207.90 NP_000087.1 
Isocitrate dehydrogenase [NADP], 
mitochondrial  3 46,660.50 NP_008830.2 
Adenosylhomocysteinase  3 47,717.10 NP_001229602.1 
Malate dehydrogenase, mitochondrial  8 35,566.00 NP_005909.2 
Aldehyde dehydrogenase, mitochondrial  12 56,381.40 NP_000683.3 
Heat shock cognate 71 kDa protein  14 70,806.60 NP_006588.1 
Proteasome subunit alpha type-4  7 29,586.00 NP_001096137.1 
Aspartate aminotransferase, mitochondrial  5 47,518.60 NP_002071.2 
78 kDa glucose-regulated protein  8 21,008.00 
 NP_005338.1 
  
Proteasome subunit beta type-5  4 26,490.50   
Fatty acid synthase  7 273,427.10 NP_004095.4 
Heterogeneous nuclear ribonucleoprotein R  3 34,225.40 NP_001095868.1 
Serpin B6    42,622.90 NP_001258754.1 
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Integrin beta-1  3 88,415.10 NP_391988.1 
Desmoplakin  32 331,781.40 NP_004406.2 
Clathrin heavy chain 1  5 191,592.90 NP_004850.1 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  4 70,391.60 NP_000009.1 
T-complex protein 1 subunit theta  6 59,621.00 NP_006576.2 
Collagen alpha-1(XIV) chain  2 193,516.10 NP_004361.3 
Spectrin alpha chain, non-erythrocytic 1  15 284,542.70 NP_001123910.1 
Filamin-B  16 278,158.80 
AAL68442.1 
   
Sodium/potassium-transporting ATPase 
subunit alpha-1  8 112,899.50 NP_001153706.1 
4-trimethylaminobutyraldehyde 
dehydrogenase  6 54,849.80 NP_000687.3 
Puromycin-sensitive aminopeptidase  7 103,279.10 NP_006301.3 
Filamin-A  13 280,729.40 
BAJ83965.1 
   
Envoplakin  2 231,604.40 NP_001979.2 
Collagen alpha-1(VII) chain  12 295,217.50 NP_000085.1 
Hexokinase-1  5 102,488.40 NP_000179.2 
Tenascin-X  12 464,307.20 NP_061978.6 
Fibrillin-1  2 312,226.00 NP_000129.3 
 
Proteins in non S9 fraction Peptide Mol Weight NCBI identification 
Histone H4 type VIII  4 11439.8 NP_003486.1  
Galectin-7  3 15074.7 NP_002298.1  
Keratin, type II cytoskeletal 2 epidermal  15 0 NP_000414.2 
ATP synthase subunit beta, mitochondrial  2 137923.7 NP_001677.2 
Keratin, type II cytoskeletal 1  17 66040.3 NP_006112.3 
Keratin, type I cytoskeletal 10  20 58828.8 NP_000412.3 
Annexin A2  20 38606.1 AAH68065.1 
Desmoglein-3  4 113748.9 NP_001935.2 
Desmoglein-1 14 99970.6 NP_001933.2 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2  2 37331.8   
Ig gamma-1 chain C region  4 36105 PT0368  
Fatty aldehyde dehydrogenase  6 54849.8 NP_001026976.1 
Desmocollin-1  18 61399.7 NP_077739.1 
Plakophilin-1  13 82862.7 NP_000290.2 
Annexin A1  10 54391.7 NP_000691.1 
Keratin, type II cytoskeletal 5  14 62379.6 NP_000415.2 
Annexin A5  5 35938.6 NP_001145.1 
Annexin A4  6 35884.3 NP_001144.1 
Synaptic vesicle membrane protein VAT-1 
homolog  2 41919.8 
NP_006364.2 
   
Capsid protein  3 58774.9   
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Plasma membrane calcium-transporting 
ATPase 4  2 137923.7 NP_001675.3 
Annexin A8-like protein 2  4   NP_001677.2 
Cytochrome b-c1 complex subunit 2, 
mitochondrial  3 48443.4 NP_003357.2 
Sodium/potassium-transporting ATPase 
subunit alpha-1  15 112899.5 NP_001153706.1 
Junction plakoglobin  4 81822.1 NP_002221.1 
Serum albumin  12 69366.9 NP_000468.1 
Voltage-dependent anion-selective channel 
protein 1  5 30773.9 NP_003365.1 
Lysosome membrane protein 2  2 54291.7 
  
NP_001191184.1 
  
Protein disulfide-isomerase A3  7 56784.6 NP_005304.3 
NADH-cytochrome b5 reductase 1  5 34096.1 NP_057327.2 
Cathepsin D  3 44553 NP_001900.1 
Prohibitin  5 29804.6 AAB21614.1 
Integrin beta-1  4 88415.1 NP_391988.1  
Copine-3  7 60131.6 NP_003900.1 
Glutamate dehydrogenase 1, mitochondrial  9 331781.4 NP_005262.1 
Stress-70 protein, mitochondrial  2 73742.4 
NP_004125.3 
   
Glycine amidinotransferase, mitochondrial  2 48456.6 NP_001473.1  
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial  2 29651.8 NP_005994.2  
Keratin, type I cytoskeletal 9  6 62065.9 NP_000217.2 
Prenylcysteine oxidase 1  4 56642.2 
  
NP_057381.3 
   
Protein disulfide-isomerase  6 57118.1 NP_000909.2 
Aspartate aminotransferase, mitochondrial  2 47434.6 NP_001273149.1 
Cytochrome b-c1 complex subunit 1, 
mitochondrial  4 52645.9 NP_003356.2 
Clathrin heavy chain 1  2 61055.7 NP_004850.1 
Alpha-actinin-4  9 104857.2 NP_004915.2 
Annexin A7  6 52740.5 AAH02632.1 
Voltage-dependent anion-selective channel 
protein 2  5 31620.5 NP_003366.2 
Ras GTPase-activating-like protein 
IQGAP1  2 189258.6   
Trifunctional enzyme subunit beta, 
mitochondrial  4 83001.9 NP_001268441.1 
Adipocyte plasma membrane-associated 
protein  3 46481.5 NP_065392.1 
78 kDa glucose-regulated protein  12 72334.7 NP_005338.1 
Very long-chain specific acyl-CoA 4 70391.6 NP_001029031.1 
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dehydrogenase, mitochondrial  
Malate dehydrogenase, mitochondrial  6 35566 NP_001269332.1 
Heat shock 70 kDa protein 1A/1B  5 70054 NP_005336.3 
Ras-related C3 botulinum toxin substrate 1  3 48443.4 P63000.1 
Integrin alpha-6  4 126609 NP_000201.2 
Aldehyde dehydrogenase, mitochondrial  7 56381.4 NP_001191818.1 
60 kDa heat shock protein, mitochondrial  3 44553 NP_002147.2 
Sulfide:quinone oxidoreductase, 
mitochondrial  3 49962 NP_067022.1 
Desmoplakin  12 60131.6 AAI40803.1 
Endoplasmic reticulum resident protein 29  4 28994.9 NP_006808.1 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial  7 79468.5 NP_001186910.1 
Lanosterol synthase  5 83310 AAB36220.1 
Endoplasmin  8   NP_003290.1 
Protein disulfide-isomerase A4  5 72934 NP_004902.1 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1  6 68571 NP_002941.1 
Aconitate hydratase, mitochondrial  4 85428 NP_001089.1 
Integrin beta-4  8 202166.7 NP_000204.3 
Glycerol-3-phosphate dehydrogenase, 
mitochondrial  9 80854.6 NP_000399.3 
Calcium-binding mitochondrial carrier 
protein Aralar1  2 191592.9 Q6NUK1.2 
Peptidyl-prolyl cis-trans isomerase A  5 18012.9 NP_066953.1 
Transmembrane protein 43  5 44876.8 NP_077310.1 
Integrin alpha-2  6 129297.9 NP_002194.2 
Acyl-CoA dehydrogenase family member 
9, mitochondrial  4 68762.8 NP_054768.2 
Endoplasmic reticulum aminopeptidase 1  5 107237.9 AIY60633.1 
Hexokinase-1  14 102488.4 NP_000179.2 
Trifunctional enzyme subunit alpha, 
mitochondrial  13 83001.9 NP_000173.2 
Epidermal growth factor receptor  4 134279.2 ADZ75461.1 
Alpha-2-macroglobulin-like protein 1  12 161108.2 NP_653271.2 
Serotransferrin  6 77064.3 NP_001054.1 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2  4 114793.9 P16615.1 
Myosin-9  24 226537.5 NP_002464.1 
Cytosolic phospholipase A2 zeta  2 95084.2   
Golgi apparatus protein 1  6 134553.9 NP_036333.2 
Myosin-14  15 227872.6 NP_001139281.1 
Prominin-2  3 91883.1 
  
NP_001159449.1 
   
Myoferlin  13 234715.6 AAF27176.1 
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Synaptophysin-like protein 1  3 28566.1 EAL24402.1 
Filamin-A  8 280729.4 NP_001447.2 
UDP-glucose:glycoprotein 
glucosyltransferase 1  5 177195 NP_064505.1 
NAD(P) transhydrogenase, mitochondrial  6 113899.2 NP_892022.2 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial  3 50817.8 
NP_009034.2 
   
Myosin-10  5 229002 NP_001243024.1 
Profilin-1  2 15054.3 
  
NP_005013.1 
   
Keratin, type II cytoskeletal 3  2 64418.9 NP_476429.2  
Spectrin alpha chain, non-erythrocytic 1  2 274613.4 NP_001123910.1  
Cation-independent mannose-6-phosphate 
receptor 3 9 274372.7 NP_000867.2 
Serpin A12  3 47177.8 NP_776249.1 
Matrilin-2  2 106836.1 
NP_002371.3 
   
  
 
 
Table 6. Quantitative expression overview of all proteins identified in S9 & NS9 fractions, based on the presence of ≥2 
different tryptic peptides identified in all the 8 donors. 
 
Identified proteins in S9 fraction Peptide Mol Weight NCBI identification total protein level 
14-3-3 protein epsilon  4 29,175.00 NP_006752.1 930133.0375 
14-3-3 protein sigma  7 27,774.80   2027747.541 
14-3-3 protein zeta/delta  5 27,745.90   941868.7524 
Alpha-2-macroglobulin  2 163,289.90 NP_000005.2 1014109.375 
Alpha-2-macroglobulin-like protein 1  3 161,108.20   859946.0333 
Alpha-1-antichymotrypsin  3 47,653.00 NP_001076.2 1207017.111 
Aspartate aminotransferase, mitochondrial  5 47,518.60 NP_002071.2 352056.376 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  4 70,391.60 NP_000009.1 230,036.12 
Actin, cytoplasmic type 5  6 41,851.00   4216398.692 
Alpha-actinin-4  14 41,851.00 NP_004915.2 598378.2526 
Fatty aldehyde dehydrogenase  4 54,849.80 NP_001026976.1 488745.0125 
4-trimethylaminobutyraldehyde dehydrogenase  6 54,849.80 NP_000687.3 143799.3947 
Serum albumin  24 69,366.90 NP_000468.1 7814385.116 
Aldehyde dehydrogenase, mitochondrial  12 56,381.40 NP_000683.3 370722.0319 
Fructose-bisphosphate aldolase A  3 39,420.60 CAA30270.1 960654.7222 
Fructose-bisphosphate aldolase C  2 39,420.60   1374402.9 
Annexin A1  7 38,715.90 NP_000691.1 532824.8548 
Annexin A2 12 38,606.10 AAH68065.1 1499714.794 
Annexin A4  6 35,884.30 NP_001144.1 441318.7417 
Annexin A5  4 35,938.60 NP_001145.1 452793.0125 
Annexin A7  2 52,740.50 AAH02632.1 679794.1 
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Actin-related protein 3  3 47,371.90 NP_065178.1 940328.5556 
Sodium/potassium-transporting ATPase subunit alpha-1  8 112,899.50 NP_001153706.1 154457.8661 
Transforming growth factor-beta-induced protein ig-h3  3 74,682.90 NP_000349.1 518188.64 
Bleomycin hydrolase  3 52,562.60 NP_000377.1 1973558.667 
Calpain-1 catalytic subunit  5 81,892.60 NP_001185798.1 614430.2676 
Caspase-14  6 27,679.80 NP_036246.1 701406.8438 
Catalase  10 59,756.50 NP_001743.1 426,343.14 
Cathepsin D  4 44,553.00 NP_001900.1 636870.7506 
Ceruloplasmin  3 122,207.90 NP_000087.1 417680.7889 
Clathrin heavy chain 1  5 191,592.90 NP_004850.1 267111.928 
Complement C3  3 187,149.10 NP_000055.2 1000123.822 
Complement C3  7 187,149.10   666487.8167 
Collagen alpha-3(VI) chain  20 343,667.40 NP_476508.2 520390.0695 
Collagen alpha-1(VII) chain  12 295,217.50 NP_000085.1 111738.9952 
Collagen alpha-1(XIV) chain  2 193,516.10 NP_004361.3 171884.4428 
Collagen alpha-1(XVIII) chain  3 178,187.70 NP_001846.3 978245.7556 
Desmoplakin  32 331,781.40 NP_004406.2 278568.0003 
Glutamate dehydrogenase 1, mitochondrial  10 61,399.70 NP_005262.1 462553.106 
Dihydrolipoyl dehydrogenase, mitochondrial  2 61,399.70   536,127.65 
Desmocollin-1  6 99,988.10 NP_077739.1 740337.5008 
Elongation factor 2  5 50,119.40 NP_001952.1 922921.5104 
Alpha-enolase  8 47,170.20 NP_001419.1 833333.6047 
Epiplakin 13 555,615.40 NP_112598.3 1107208.309 
Envoplakin  2 231,604.40 NP_001979.2 111878.975 
Fatty acid synthase 7 273,427.10 NP_004095.4 292577.0612 
Fibrillin-1  2 312,226.00 NP_000129.3 33,496.14 
Fibrinogen beta chain  5 55,928.60 NP_005132.2 535050.412 
Fibronectin  4 262,616.90   512725.0778 
Filamin-A  13 280,729.40   118903.6471 
Filamin-B  16 278,158.80   160342.5445 
Glyceraldehyde-3-phosphate dehydrogenase  3 36,053.40 CAA25833.1 9883716.667 
Glucose-6-phosphate isomerase  3 31,085.70 NP_001171651.1 744998.88 
Rab GDP dissociation inhibitor beta  7 50,584.10 NP_001108628.1 424112.7316 
Gelsolin  4 85,697.80 NP_000168.1 2808048.563 
Gamma-glutamylcyclotransferase  4 21,008.00 NP_076956.1 939465.4813 
78 kDa glucose-regulated protein 8 21,008.00   339769.0547 
Glutathione S-transferase Mu 3  5 25,746.50 NP_000840.2 883964.498 
Histone H2B type 1-N  4 13,950.80 NP_003511.1 9276818.419 
Histone H4  6 11,269.60 NP_778224.1 2.11E+07 
Hemoglobin subunit beta  2 15,998.00 NP_000509.1 8091235.975 
Hemopexin  2 51,676.50 NP_000604.1 959554.625 
Heterogeneous nuclear ribonucleoprotein U-like protein 1  2 96,003.10 NP_008971.2 435139.8 
Heterogeneous nuclear ribonucleoprotein R  3 34,225.40 NP_001095868.1 290640.0111 
Heat shock 70 kDa protein 1B  12 70,230.20 NP_005337.2 933790.8938 
Heat shock protein HSP 90-beta  3 84,778.20 NP_031381.2 584640.5444 
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Heat shock cognate 71 kDa protein  14 70,806.60 NP_006588.1 369251.7632 
Hexokinase-1  5 102,488.40 NP_000179.2 89,650.54 
Isocitrate dehydrogenase [NADP], mitochondrial  3 46,660.50 NP_008830.2 391483.9967 
Ig alpha-1 chain C region  2 37,754.70 B45874 6137233 
Ig gamma-1 chain C region  6 36,105.00 PT0368 13009588.77 
Ig mu chain C region  3 49,305.70 S37768 494947.7222 
Ig kappa chain C region  3 11,608.60 P01834.1 9278070.489 
Ras GTPase-activating-like protein IQGAP1  4 189,258.60 NP_003861.1 417,682.29 
Integrin beta-1  3 88,415.10 NP_391988.1 282986.4922 
Keratin, type I cytoskeletal 10  14 58,828.80 NP_000412.3 5.31E+06 
Keratin, type I cytoskeletal 14  8 51,562.50 NP_000517.2 2.51E+06 
Keratin, type I cytoskeletal 9  2 62,065.90 NP_000217.2 1901922.25 
Keratin, type II cytoskeletal 2 epidermal  18 65,433.90 NP_000414.2 2.17E+07 
Keratin, type II cytoskeletal 1  17 66,040.30 NP_006112.3 8.30E+06 
Pyruvate kinase PKM 7 57,937.50 NP_001193728.1 1203846.175 
L-lactate dehydrogenase A chain  3 36,689.20 NP_005557.1 1596937.211 
Prelamin-A/C  4 74,140.70 NP_733821.1 1537311.731 
Malate dehydrogenase, cytoplasmic  2 36,426.90 NP_001186040.1 1029587.5 
Malate dehydrogenase, mitochondrial  8 35,566.00 NP_005909.2 382943.1766 
Myosin-9  2 226,537.50 NP_002464.1 3198661.75 
Myosin light polypeptide 6  2 16,929.80 NP_066299.2 690064.4 
Protein disulfide-isomerase  5 57,118.10 NP_000909.2 977765.152 
Protein disulfide-isomerase A3  4 56,784.60 NP_005304.3 1004540.056 
Phosphatidylethanolamine-binding protein 1 2 21,056.90 NP_002558.1 2587409.5 
Phosphoglycerate kinase 1  5 44,615.30 NP_000282.1 482,026.88 
Junction plakoglobin  10 81,801.90 NP_068831.1 1168557.885 
Plectin  13 531,783.90 NP_112598.3 822,219.49 
Periostin  4 93,318.00 NP_006466.2 838200.5319 
Peptidyl-prolyl cis-trans isomerase A  5 18,012.90 NP_066953.1 2227722.52 
Peptidyl-prolyl cis-trans isomerase B  4 18,012.90   1052328.563 
Peroxiredoxin-1  7 22,110.90 NP_859048.1 913130.0776 
Proteasome subunit alpha type-4  7 29,586.00 NP_001096137.1 355092.5367 
Proteasome subunit alpha type-7  4 29,586.00   681,252.64 
Puromycin-sensitive aminopeptidase  7 103,279.10 NP_006301.3 121,318.42 
Proteasome subunit beta type-1  2 26,490.50 NP_002784.1 1595880.55 
Proteasome subunit beta type-5  4 26,490.50   314958.1688 
Ribonuclease inhibitor  5 49,974.40 NP_976320.1 570,206.47 
60S ribosomal protein L10a  3 24,832.00 NP_009035.3 964,035.94 
60S ribosomal protein L12  4   NP_000967.1 1313476.569 
60S ribosomal protein L5  4 34,363.50 NP_000960.2 1503853.044 
60S acidic ribosomal protein P0  3 34,371.40 NP_444505.1 1927008 
40S ribosomal protein S18  3 17,719.30 NP_072045.1 1352747.622 
Ubiquitin-40S ribosomal protein S27a  3 17,965.60 NP_001129064.1 2988518.144 
40S ribosomal protein S3  3 29,945.30 NP_001243731.1 1734167.111 
40S ribosomal protein SA  3 33,021.30 NP_001012321.1 1500066.2 
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Adenosylhomocysteinase  3 47,717.10 NP_001229602.1 388707.7556 
Serpin B12  3 46,277.70 NP_536722.1 1879312.567 
Serpin B5  8 42,101.80 NP_002630.2 623202.6639 
Serpin B6    42,622.90 NP_001258754.1 284568.0063 
Spectrin alpha chain, non-erythrocytic 1  15 284,542.70 NP_001123910.1 163538.2191 
Transaldolase  2 37,541.70 NP_006746.1 2174310.65 
T-complex protein 1 subunit theta  6 59,621.00 NP_006576.2 229140.0861 
Tenascin-X  12 464,307.20 NP_061978.6 86319.88958 
Transitional endoplasmic reticulum ATPase  7   NP_009057.1 923450.0708 
Protein-glutamine gamma-glutamyltransferase E  7 89,786.00 NP_003236.3 605587.9857 
Thioredoxin 2 11,737.30   691253.4 
Triosephosphate isomerase 5 30,790.80 NP_000356.1 858167.652 
Serotransferrin  22 77,064.30 NP_001054.1 812051.7413 
Tripartite motif-containing protein 29  5 65,835.70 NP_036233.2 812051.7413 
Ubiquitin-like modifier-activating enzyme 1  4 117,850.30 NP_003325.2 422553.4375 
WD repeat-containing protein 1  2 66,193.20 NP_059830.1 740171.1175 
X-ray repair cross-complementing protein 6  5 69,846.40 NP_001460.1 428459.2008 
Zinc-alpha-2-glycoprotein  5 34,258.60 NP_001176.1 1532837.975 
 
 
Identified proteins in Non S9 fractions Peptide Mol Weight NCBI identification 
total protein 
level 
HLA class I histocompatibility antigen, A-34 alpha chain  2 41054.6 CAK22320.1 5,605,276.74 
Alpha-2-macroglobulin-like protein 1  12 161108.2 NP_653271.2 54765.86264 
Aspartate aminotransferase, mitochondrial  2 47434.6 NP_001273149.1 251,001.76 
Acyl-CoA dehydrogenase family member 9, mitochondrial 4 68762.8 NP_054768.2 89,289.24 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  5 70391.6 NP_001029031.1 171,421.26 
Aconitate hydratase, mitochondrial  4 85428 NP_001089.1 99,867.43 
Actin-5C  6 104857.2 NP_004915.2 3482303.944 
Alpha-actinin-4  10 54849.8 NP_001026976.1 216735.2701 
Fatty aldehyde dehydrogenase  7 69366.9 NP_000468.1 1,091,544.14 
Serum albumin  13 56381.4 NP_001191818.1 394966.0581 
Aldehyde dehydrogenase, mitochondrial  7 54391.7 NP_000691.1 406498.9678 
Annexin A11  6 38606.1 AAH68065.1 117205.3053 
Annexin A1  11 35884.3 NP_001144.1 985486.9702 
Annexin A2  20 35938.6 NP_001145.1 2.42E+06 
Annexin A4  6 52740.5 AAH02632.1 744,786.72 
Annexin A5  5 46481.5 NP_065392.1 746,993.54 
Annexin A7  6 112899.5 NP_001153706.1 337867.045 
Adipocyte plasma membrane-associated protein  3 114793.9 P16615.1 190667.5 
Sodium/potassium-transporting ATPase subunit alpha-1  15 137923.7 NP_001675.3 398346.0648 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  7 137923.7 NP_001677.2 33,831.71 
Plasma membrane calcium-transporting ATPase 4  2   NP_001677.2 475,924.39 
ATP synthase subunit beta, mitochondrial  2 58774.9   3312120.058 
Annexin A8-like protein 2  4 44553 NP_001900.1 474139.3 
Capsid protein  3 44553 NP_002147.2 879,776.90 
125 
 
Cathepsin D  4 61055.7 NP_004850.1 189,576.13 
60 kDa heat shock protein, mitochondrial  3 191592.9 Q6NUK1.2 112203.6533 
Clathrin heavy chain 1  2 60131.6 NP_003900.1 48,225.74 
Calcium-binding mitochondrial carrier protein Aralar1  2 60131.6 AAI40803.1 256,368.40 
Copine-3  7 331781.4 NP_005262.1 268737.6848 
Desmoplakin 12 61399.7 NP_077739.1 138255.8405 
Glutamate dehydrogenase 1, mitochondrial  9 99970.6 NP_001933.2 282878.0927 
Desmocollin-1  11 113748.9 NP_001935.2 1338614.263 
Desmocollin-3  7 83001.9 NP_000173.2 2777226.279 
Desmoglein-1  18 83001.9 NP_001268441.1 962,801.21 
Trifunctional enzyme subunit alpha, mitochondrial  17 134279.2 ADZ75461.1 45,315.12 
Epidermal growth factor receptor  4   NP_003290.1 58,183.18 
Endoplasmin  8 107237.9 AIY60633.1 272910.3728 
Endoplasmic reticulum aminopeptidase 1  5 83310 AAB36220.1 71,304.02 
Lanosterol synthase  5 28994.9 NP_006808.1 120,450.83 
Endoplasmic reticulum resident protein 29  4 280729.4 NP_001447.2 170,767.56 
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial  3 48456.6   63,245.85 
Filamin-A  5 37331.8   28,109.92 
Filamin-B  3 80854.6 NP_000399.3 39,331.84 
Neutral alpha-glucosidase AB  7 73742.4   177,927.36 
Glycine amidinotransferase, mitochondrial  2 72334.7 NP_005338.1 274,621.71 
Guanine nucleotide-binding protein G(i) subunit alpha-2  3 134553.9 NP_036333.2 1074524.568 
Glycerol-3-phosphate dehydrogenase, mitochondrial  9 11439.8   94754.38938 
Stress-70 protein, mitochondrial 2 70054 NP_005336.3 279,802.98 
78 kDa glucose-regulated protein  12 102488.4 NP_000179.2 178965.6314 
Golgi apparatus protein 1  6 36105   30,047.62 
Histone H4 type VIII  4 189258.6   4657862.65 
Heat shock 70 kDa protein 1A/1B  5 129297.9 NP_002194.2 157,237.22 
Hexokinase-1 14 126609 NP_000201.2 68,065.41 
Ig gamma-1 chain C region  4 88415.1   1,500,176.42 
Ras GTPase-activating-like protein IQGAP1  2 202166.7 NP_000204.3 196,644.82 
Integrin alpha-2  6 58828.8 NP_000412.3 89,768.31 
Integrin alpha-6  4 62065.9 NP_000217.2 145,452.89 
Integrin beta-1  4 0 NP_000414.2 312,924.35 
Integrin beta-4  8 66040.3 NP_006112.3 95,953.18 
Keratin, type I cytoskeletal 10  15 64418.9   4,411,763.00 
Keratin, type I cytoskeletal 14  5 62379.6 NP_000415.2 7043435 
Keratin, type I cytoskeletal 9  6 15074.7   62599 
Keratin, type II cytoskeletal 2 epidermal  15 106836.1   3907120.586 
Keratin, type II cytoskeletal 1  17 35566 NP_001269332.1 2.97E+06 
Keratin, type II cytoskeletal 3  2 274372.7 NP_000867.2 10337 
Keratin, type II cytoskeletal 5  14 229002 NP_001243024.1 813997 
Galectin-7  3 227872.6 NP_001139281.1 3793824 
Matrilin-2 2 226537.5 NP_002464.1 151.5 
Malate dehydrogenase, mitochondrial  6 234715.6 AAF27176.1 165039.6297 
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Cation-independent mannose-6-phosphate receptor  9 34096.1 NP_057327.2 6,972.51 
Myosin-10  4 79468.5 NP_001186910.1 12,468.57 
Myosin-14  15 50817.8   28,873.39 
Myosin-9  24 113899.2 NP_892022.2 29686.72939 
Myoferlin 13 95084.2   25099.1887 
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  7 56642.2   128436.3643 
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  3 57118.1 NP_000909.2 11036.26111 
NAD(P) transhydrogenase, mitochondrial 6 56784.6 NP_005304.3 12,466.14 
Nodal modulator 2  2 72934 NP_004902.1 12,422.20 
Cytosolic phospholipase A2 zeta  2 29804.6 AAB21614.1 31923.335 
Prenylcysteine oxidase 1 4 82862.7 NP_000290.2 269,201.33 
Protein disulfide-isomerase  6 81822.1 NP_002221.1 261841 
Protein disulfide-isomerase A3  12 18012.9 NP_066953.1 91978 
Prohibitin  5 15054.3   314372.632 
Plakophilin-1  13 91883.1   900093.6763 
Junction plakoglobin 4 52645.9 NP_003356.2 396757.1031 
Peptidyl-prolyl cis-trans isomerase B  4 48443.4 NP_003357.2 93,300.21 
Profilin-1 2 48443.4 P63000.1 10715.5725 
Prominin-2  3 68571 NP_002941.1 28301.10222 
Cytochrome b-c1 complex subunit 1, mitochondrial  7 54291.7   150218.81 
Ras-related C3 botulinum toxin substrate 1 3 47177.8 NP_776249.1 157021.5156 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  6 274613.4   74,897.30 
Lysosome membrane protein 2  2 49962 NP_067022.1 347,699.55 
Serpin A12  3 28566.1 EAL24402.1 4812.988889 
Immunoglobulin G-binding protein A 2 44876.8 NP_077310.1 145642.865 
Spectrin beta chain, non-erythrocytic 1  3 77064.3 NP_001054.1 3805.873333 
Sulfide:quinone oxidoreductase, mitochondrial  3 29651.8   140179.9778 
Synaptophysin-like protein 1 3 177195 NP_064505.1 17207.54778 
Transmembrane protein 43  5 41919.8   91,195.67 
Serotransferrin 6 30773.9 NP_003365.1 36856.52104 
Cytochrome b-c1 complex subunit Rieske, mitochondrial 2 31620.5 NP_003366.2 274431.75 
UDP-glucose:glycoprotein glucosyltransferase 1  5     12879.1984 
Synaptic vesicle membrane protein VAT-1 homolog  2     598768.175 
Voltage-dependent anion-selective channel protein 1  5     309891 
Voltage-dependent anion-selective channel protein 2  5     62486 
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Figure 23. Proposed regulation of Nrf2 and NF-κB by protein modification or GSH depletion (Chia et al.,2010) 
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Table 7. Summary of the GST Pi gene expression of control and DNCB treated HaCaT cells  
Sample copies/μg Sample copies/μg 
control-0.5h 0.00617 DNCB-0.5h 0.11812 
control-0.5h 0.00601 DNCB-0.5h 0.14544 
control-0.5h 0.00545 DNCB-0.5h 0.11449 
average  0.0058767 average  0.1260167 
control-1h 0.04175 DNCB-1h 0.0535 
control-1h 0.05215 DNCB-1h 0.05165 
control-1h 0.04122 DNCB-1h 0.05074 
average  0.04504 average  0.0519633 
control-2h 0.04472 DNCB-2H 0.02381 
control-2h 0.04789 DNCB-2H 0.03031 
control-2h 0.04359 DNCB-2H 0.02353 
average  0.0454 average  0.0258833 
control-3h 0.06284 DNCB-3H 0.0555 
control-3h 0.04988 DNCB-3H 0.04624 
control-3h 0.04852 DNCB-3H 0.04027 
average  0.0537467 average  0.0473367 
control-4h 0.05183 DNCB-4H 0.07939 
control-4h 0.06176 DNCB-4H 0.09329 
control-4h 0.05471 DNCB-4H 0.09235 
average  0.0561 average  0.0883433 
control-6h 0.07515 DNCB-6H 0.04115 
control-6h 0.04368 DNCB-6H 0.04346 
control-6h 0.06717 DNCB-6H 0.09981 
average  0.062 average  0.0614733 
control-24h 0.0012 DNCB-24H 0.01667 
control-24h 0.00041 DNCB-24H 0.01377 
control-24h 0.00049 DNCB-24H 0.0238 
average  0.0007 average  0.01808 
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Table 8. Summary of the GST Pi gene expression of control and PA treated HaCaT cells  
Sample copies/μg Sample copies/μg 
Control 0,5 0.00346 PA-0.5h 0.0152 
Control 0,5 0.00336 PA-0.5h 0.01512 
Control 0,5 0.00332 PA-0.5h 0.01534 
average 0.00338 average 0.01522 
Control-1h 0.01074 PA-1h 0.01655 
Control -1h 0.0117 PA-1h 0.01735 
Control -1h 0.01189 PA-1h 0.01781 
average 0.01144333 average 0.01723667 
Control-2h 0.0179 PA-2h 0.024598 
Control -2h 0.00989 PA-2h 0.020007 
Control -2h 0.004999 PA-2h 0.017667 
average 0.010911 average 0.020334 
Control -3h 0.01023 PA-3h 0.02467 
Control -3h 0.01069 PA-3h 0.01933 
Control 3h 0.01049 PA-3h 0.01888 
average 0.01047 average 0.02096 
Control -4h 0.01454 PA-4h 0.01533 
Control -4h 0.0146 PA-4h 0.0167 
Control -4h 0.01339 PA-4h 0.01148 
average 0.01417667 average 0.01450333 
Control -6h 0.01182 PA-6h 0.01242 
Control -6h 0.01733   
Control -6h 0.01205   
average 0.01373333 PA-24h 0.01778 
  PA-24h 0.03092 
Control -24 0.00064 PA-24h 0.02642 
  average 0.02504 
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Table 9. Summary of the GAPDH gene expression of control, DNCB and PA treated HaCaT  
Sample control copies/μg Sample copies/μg Sample  copies/μg 
C 0.5h 0.004 DNCB 0.5h 0.014 PA 0.5h 0.012 
C 0.5h 0.0039 DNCB 0.5h 0.014 PA 0.5h 0.009 
C 0.5h 0 DNCB 0.5h 0.023 PA  0.5h 0.023 
Average  0.0039 Average  0.0168 Average  0.0147 
C 1h 0.02 DNCB 1 0.01 PA  1 0.17 
C 1h 0.016 DNCB 1h 0.008 PA  1h 0.0093 
C 1h 0 DNCB 1h 0.11 PA 1h 0.101 
Average  0.018 Average  0.011 Average  0.0934 
C 2h 0.014 DNCB 2h 0.012 PA 2h 0.011 
C 2h 0.012 DNCB 2h 0.007 PA 2h 0.007 
C 2h 0 DNCB 2h 0.008 PA 2h 0.010 
Average  0.013 Average  0.009 Average  0.0094 
C 3h 0.013 DNCB 3h 0.02 PA 3h 0.02 
C 3h 0.015 DNCB 3h 0.027 PA 3h 0.025 
C 3h 0.021 DNCB 3h 0.01 PA 3h 0.015 
Average  0.016 Average  0.017 Average  0.02 
C 4h 0.039 DNCB 4h 0.09 PA 4h 0.091 
C 4h 0.018 DNCB 4h 0.038 PA 4h 0.053 
C 4h 0.089 DNCB 4h 0.015 PA 4h 0.015 
Average  0.018 Average  0.039 Average  0.055 
C 6h 0.04 DNCB 6h 0.032 PA 6h 0.038 
C 6h 0.02 DNCB 6h 0.013 PA 6h 0.022 
C 6h 0.033 DNCB 6h 0.025 PA 6h 0.027 
Average  0.03 Average  0.022 Average  0.029 
C 24h 0.12 DNCB 24h 0.02 PA 24h 0.019 
C 24h 0.098 DNCB 24h 0.0094 PA 24h 0.0096 
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Figure 24. Standard cDNA curve, performed on treated HaCaT cells using the designed 
GAPDH primers 
 
C 24h 0.112 DNCB 24h 0.01922 PA 24h 0.01899 
Average  0.11 Average  0.015 Average  0.0158 
      
